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ABSTRACT 
Although considerable advances in genomics research, with the likes of Genome-Wide Association 
Studies (GWAS), have uncovered vast quantities of genomic data regarding the genetic basis of many 
neuropsychiatric disorders, the heritability of such disorders and associated traits such as treatment 
response are not completely understood. Antipsychotic treatment response (ATR) of schizophrenia 
(SZ) is effective in only around half of all diagnosed patients. As with the disorder itself, ATR is 
known to be a complex trait with variable outcomes for patients and for which no clinical biomarkers 
exist to point towards possible indicators of treatment efficiency, often accompanied by the trial-and-
error process of treatment adjustment. The large-scale nature of studies like GWAS, have the potential 
to elucidate this ‘missing heritability’ seen in ATR outcomes, in combination with pharmacogenetics 
approaches which aim to quantify on an individual level the interaction between genetics and 
maximal treatment efficacy, as well as in avoidance of potential adverse drug reactions (ADRs). The 
data outputs from GWAS have also highlighted noncoding regions of the genome, in which many top 
resultant hits have been shown to occur, in spite of this the interpretation of many genomic results 
have been limited to the nearest gene. While genetic variants linked to aspects of treatment like ATR 
and ADRs have been found, the interpretation of such results are important in discerning functional 
consequence surrounding identification of single nucleotide polymorphisms (SNPs) in association 
with either disorder or trait surrounding the disorder, i.e. ATR. These findings in combination with 
the knowledge of noncoding regions prominent role in hosting many SNPs, draws attention to the 
potential role of regulatory mechanisms interacting within ATR systems or pathways that have 
otherwise been disregarded. This study investigated the role of miRNA-mediated regulation in ATR, 
with parallel approaches designed to investigate the potential of miRNA implicated SNPs and 
miRNA-targeted genes in a bioinformatic systems genetics approach to reveal underlying regulatory 
consequences interacting in SZ ATR. The most significant finding identified a novel association of 
the variant, rs895808, with an improved treatment response for the negative symptom domain of the 
Positive and Negative Syndrome Scale (PANSS). The SNP was found to have consequential impact 
in disrupting the following miRNAs conserved sites; miRNA-548ac, miRNA-548d-3p, miRNA-
548h-3p and miRNA-548z, and is linked to miRNA-4536 with unknown regulatory impact. FUMA 
analysis identified implicated pathways from miRNA-targeted genes and SNPs, with regulation of 
apoptosis and phosphodiesterase pathways presenting. Both pathways have largely been implicated 
in SZ pathophysiology, however this is the first identification with regard to miRNA-involvement to 
our knowledge and suggests an alternate avenue for investigation into the ATR of SZ.  
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OPSOMMING 
Alhoewel aansienlik baie vordering in geonomiese navorsing, soos die van Genoomwye 
Assosiasiestudies (GWAS), tot groot hoeveelhede geonomiese data aangaande die genetiese basis 
van baie neuropsigiatriese toestande gelei het - word die oorerflikheid van sulke toestande en 
geassosieerde kenmerke soos behandelingsrespons nog nie volledig verstaan nie. Die antipsigotiese 
behandeling van skisofremie (SZ) is slegs effektief in min of meer die halfte van gediagnoseerde 
pasiente. Nes die toestand self is die antipsigotiese behandelingsrespons (ATR) bekend daarvoor om 
‘n ingewikkelde eienskap te wees met veelvuldige moontlike uitkomste vir pasiente. Daar bestaan 
ook geen klieniese biomerkers om moontlike behandelingseffektiwiteit meer aan te dui nie, en 
behandeling gaan dikwels gepaard met steekproef proses van probeer en aanpas tot en met sukses 
behaal word. Die grootskaalse natuur van studies soos GWAS die potensiaal om hierdie ‘onbekende 
oorerflikheid’ wat in ATR gesien word te verklaar.  In kombinasie daarmee help farmakogenetiese 
benaderings wat die interaksie tussen genetika en maksimum behandelingseffektiwitiet, asook 
vermyding van potensiële ongunstige medisyne reaksies (ADRs) om op ‘n indivduële vlak te teiken. 
Die dataopbrengste van GWAS het ook nie nie-koderende streke van die genoom uitgewys waarin 
baie van die mees gereëlde vangskote voorgekom het. Ten spyte van hiervan is die interpretasie van 
baie geonomiese uitkomstes beperk tot die naaste enkele geen. Terwyl genetiese variante gekoppel 
aan behandelingsaspekte soos ATR en ADRs al gevind is, is die interptretasie van hierdie data baie 
belangrik. Dit kan gebruik word om die funksionële nagevolge rondom die identifikasie van enkel 
nukleotied polimorfismes (SNPs) te onderskei, in genootskap met die toestand of ‘n kenmerk van die 
toestand - d.w.s ATR. Hierdie bevindinge, tesame met die kennis van die prominente rol wat nie-
koderende streke speel in die huisvesting van SNPs vestig aandag op die potensiële rol van beherende 
meganismes wat op mekaar inwerk binne ATR sisteme of padweë wat andersins ter syde gesit sou 
word. Hierdie studie het die rol van miRNA-bemiddelde regulasie in ATR ondersoek, met paralelle 
benaderinge ontwerp om die potensiaal van miRNA geimpliseerd in SNPs en miRNA-geteikende 
gene in bioinformatiese sisteemsgenetieka te ondersoek om onderliggende beheersnagevolge wat met 
SZ ATR verkeer. Die mees betekenisvolle bevinding was ‘n nuwe assosiaise van die rs895808 
variant, wat ‘n verbeterde behandelingsrespons vir negatiewe simptome op die Positiewe- en 
Negatiewe Sindroomskaal (PANSS). Dié SNP was gevind om gevolglike impak te om die 
gekonserfeerde streke van volgende miRNAs te versteur: miRNA-548ac, miRNA-548d-3p, miRNA-
548h-3p en miRNA-548z. Dit is ook gekoppel aan miRNA-4536 met onbekende beherende impak. 
FUMA analise het padweë van geimpliseerde miRNA-geteikende gene geïdentifiseer, asook SNPs 
wat apoptose en fosodïesterase padweë reguleer. Beide padweë is grotendeels geïmpliseerd in SZ 
patofisiologie, alhoewel dit die eerste identifikasie met betrekking tot miRNA is en ‘n alternatiewe 
roete vir ondersoek van ATR van SZ is. 
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Around 450 million people are burdened with a neuropsychiatric (NP) disorder, projecting mental 
disorders as one of the leading causes of detrimental health and disability globally (NMH 
Communications, 2001). Despite evident prevalence of these disorders worldwide, research is yet to 
unravel the complexities underpinning the causality, and subsequently adequate treatment 
development is hampered. Even though the considerable burden of these disorders, including adverse 
human, economic and social effects, has been made clear, efficient treatment of such disorders has 
failed to alleviate all such associated burdens (Kassebaum et al., 2016; Vigo et al., 2016).  These 
disorders, including anxiety disorders and schizophrenia (SZ), emerged in the top 20 causes of global 
burden of disease in 2013 and was shown to reach epidemic proportions in low-income regions of 
the globe (Mayosi et al., 2009a; Vigo et al., 2016). Related behavioural, social, cognitive and 
perceptual disruptions are seen across individuals afflicted with SZ, Bipolar Disorder (BD), as well 
as both Obsessive-compulsive Disorder (OCD) and Autism Spectrum Disorder (ASD) (O’Connell et 
al., 2018a; Smeland et al., 2019). A vast overlap is seen in the clinical symptomology surrounding 
these disorders, for example; cognitive and perceptual deficits are shared between SZ, BD, ASD, and 
OCD whereby learning, mood, memory, perception and executive function are affected (Gilman et 
al., 2014; Krystal and State, 2014; O’Connell et al., 2018b). 
 
Concurrent twin, family and adoption studies have identified that neuropsychiatric disorders like SZ 
and BD have a genetic basis and are influenced by environmental factors (Smeland et al., 2019). 
Much deliberation has been put forward regarding the proposed genetic model by which these 
disorders adhere and manifest, including the “heterogeneity model”, the “common disease-common 
variant model” and more recently the “omnigenic model” (Yang et al., 2005; Peedicayil and Grayson, 
2018). The “heterogeneity” model assumes that many individually rare genetic variants of large 
effect-sizes contribute towards the disorder, while the “common disease-common variant” model 
presents an opposing hypothesis that many relatively common variants of small effect-sizes interact 
in the manifestation of the disorder (Yang et al., 2005). The “omnigenic model” suggests that a vast 
number of causal variants with tiny effect-sizes occur widely across the genome and genetic 
contribution to disease is heavily clustered in regions known to be transcribed or marked by active 
chromatin (Boyle et al., 2017). With an increasing number of individuals reported as afflicted by at 
least one mental disorder, unraveling the genetic architecture of such disorders has taken precedence. 
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Shortcomings observed in treatment efficacy have also stimulated a shift in focus in genomics 
research regarding NP disorders (Drogemöller et al., 2014a). 
 
1.2.Schizophrenia – incidence and impact 
 
According to the most recent Global Epidemiology and Burden of Schizophrenia study, SZ accounts 
for 13.4 million years of life lived with a disability globally (Charlson et al., 2018). This multifaceted, 
heritable disorder affects approximately 1% of the global population. Despite this seemingly low 
incidence rate, SZ ranked as the 12th most disabling disorder amongst 310 diseases and injuries 
globally in 2016 (Charlson et al., 2018). In South Africa neuropsychiatric disorders like SZ rank third 
in contribution to overall disease burden (“Mental Health Policy Framework,” n.d.).  
 
1.3.Symptomology and progression  
 
Schizophrenia is a chronic neurodevelopmental disorder, with varied symptomology divided into 
positive, negative and general/cognitive categories (Rund, 2018; Weïwer et al., 2013a). The positive 
symptomology most commonly associated with SZ are symptoms described as added to the normal 
behavioural repertoire, whereas the negative are a lack of or decrease in certain normal behavioural 
or developmental characteristics (Weïwer et al., 2013a). For instance, individuals afflicted with SZ 
may experience psychotic symptoms like hallucinations and delusions with impairments in speech, 
apathy and loss in motivation (Figure 1.1). Alongside these symptoms are considerable 
psychopathological symptoms like cognitive deficits and motor abnormalities. Collectively the 
symptoms and the severity of the disorder have an immense impact on the patients quality of life 










Figure 1.1 Symptomology of SZ and resultant impact on quality of life (Weïwer et al., 2013a). 




The Positive and Negative Syndrome Scale (PANSS) was developed to quantify these symptoms 
with regard to severity, response to treatment, relapse and remission of schizophrenia. Symptoms 
are measured categorically with severity determined numerically (Kay et al., 1987). This scale 
combined items of the Brief Psychiatric Rating Scale (Overall and Gorham, 1962) and the 
Psychopathology Rating Schedule (Singh and Kay, 1975) to assess both positive, negative and 
general psychopathology in complete definitions. 
 
The onset of such symptoms is seen in adolescence to early adulthood however this onset and eventual 
progression is not always amenable to strict categorical classification (Parnas, 1999; Rund, 2018). 
These clinical features, age of onset and the course of illness including inter-episode recovery can 
vary widely amongst individual patients (Desbonnet et al., 2012). Despite difficulties in identifying 
predetermined phases of this disorder in its progression, efforts have been made to surmise 
epidemiological, clinical and phenomenological aspects of the evolution of SZ, into premorbid, 
prodromal, pre-psychotic to psychotic and psychotic to stable phases (Figure 1.2) (Parnas, 1999). The 
onset of this disorder is generally pinpointed by the first psychotic episode, followed by subsequent 
episodes separated by brief periods of remission (American Psychiatric Association and others, 
2013). The so-called stable phase encapsulates lingering negative and cognitive symptoms with a 




















Although a standardised, absolute collective of symptomology at diagnosis is lacking, there is a 
general agreement regarding clinical characteristics in the expression of SZ (Figure 1.3). Given the 
associated symptomology and resulting functional impairments, SZ has been noted as one of the most 
debilitating mental disorders with regard to impact on both individuals and society (Tandon et al., 
2009).  
 
Figure 1.3 Clinical characteristics of schizophrenia for diagnoses (Tandon et al., 2009). Reprinted 
with permission from Elsevier 
 
In societal context, SZ is a very costly disorder; predominantly with regard to functional impairment 
and subsequent reduced productivity of sufferers, profound stigmatization as well as varied and 
inadequate efficacy of currently available treatment (Carr et al., 2004; Tandon et al., 2009). Although 
the course of SZ appears distinct, the exacerbations and remission periods are resolved with varying 
extent across individual sufferers during the course of illness (Andreasen et al., 2005; Haro et al., 
2008) and those individuals suffering have a chronic struggle with both relapse and persistence of 




SZ is commonly diagnosed using the Diagnostic and Statistical Manual of Mental Disorders (DSM) 
in a clinical interview based on characteristics as outlined by the manual (American Psychiatric 
Association and others, 2013). This is not the only manual of its kind used in diagnoses, others include 
the International Classification of Diseases (ICD) (World Health Organization, 1992), with both 
manuals having high clinical diagnostic reliability. However, the most commonly employed is the 
DSM, throughout which the definition of SZ has evolved over six editions (DSM-I, DSM-II, DSM-
III, DSM-III-R, DSM-IV, DSM-IV-TR and DSM-V) with the fourth edition notably having high 
clinical reliability and validity (Tandon et al., 2013, 2009). Despite the constant alterations to this 
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manual, three core concepts have contributed towards the definition of SZ; 1) the Kraepelinian accent 
on avolition, chronicity and poor outcome (Kraepelin, 1971), 2) the Bleulerian view on negative 
symptoms (Bleuler, 1950) and 3) the Schneiderian positive symptoms (Schneider, 1959). Given the 
reliability of the DSM-IV, diagnostic criteria have been carried over to the current version, DSM-V, 
however the heterogeneity of the disorder was poorly explained by the subtypes outlined in previous 
versions (paranoid, catatonic, disorganized, schizoaffective, undifferentiated, and residual) and has 
since been abandoned to preserve diagnostic reliability (Tandon, 2014). Characteristic symptoms of 
schizophrenia as retained from the DSM-IV are delusions, hallucinations, disorganized speech, 
exceptionally disorganized or catatonic behavior and negative symptoms like those described 
previously (section 1.3.). For a diagnosis to be made in the clinical interview, at least two of the five 
characteristic symptoms of SZ need to be met and present for a minimum 1-month period (Tandon et 
al., 2013). 
 
The heterogeneity of SZ introduces another problem concerning diagnosis, as there is varied and 
significant clinical overlap between psychiatric disorders (O’Connell et al., 2018b). This is further 
complicated by excessive comorbidity observed amongst many mental disorders as well (Figure 1.4). 
Conflicting ideas and research have introduced discord in the narrative of defining mental disorders 
into distinct clinical categories, with many clinicians struggling to fit individual patients into neatly 
defined symptom ‘boxes’, suggesting rather a spectrum of ‘dimensionality’ to account for this overlap 
(Adam, 2013).  
 
Figure 1.4 Proposed spectrum of mental illness in dimensional approach to diagnosis (Adam, 2013). 
Reprinted with permission from Nature News 
 
The spectrum portrays mental illness as a dysregulation of normal processes and categorically 
separating these disorders may been seen as inhibitory towards research contributing towards the 
refinement of diagnoses processes. This phenomenon is described by comorbidities, i.e. the 
occurrence of two or more mental disorders in one individual, which is not all that uncommon with 
as many as 45% of patients manifesting mental illnesses in this manner (van Loo and Romeijn, 2015). 
Dichter and colleagues (Dichter et al., 2012) provided evidence of these overlapping DSM disorders 
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with anxiety and mood disorders resulting in part to hyperactivity of the amygdala region in the brain 
and those suffering SZ and post-traumatic stress disorder sharing aberrant activity in the prefrontal 
cortex. Given the insurmountable evidence regarding the prevalence of comorbidities, it seems fitting 
that the diagnostic tool would be in line with this representation and encapsulate all possible 
symptoms manifested across psychiatric disorders. This is a controversial and heavily debated view, 
however it cannot afford to be ignored given the current prevalence of mental illness and the lack of 
satisfactory answers to explain the high rates of comorbidity in psychiatric patients (van Loo and 





Given the complexity underlying disorders like SZ, it has been agreed that it is not the result of a 
simple single gene – unlike Mendelian disorders. This has given rise to hypotheses on the genetics 
associated with this polygenic disorder and disease manifestation in patients. Broadly speaking, 
polygenic disorders have been proposed to follow various models of transmission, as described 
previously (section 1.1).  
 
The etiology of SZ involves various risk factors, broadly defined as genetic or environmental. 
Throughout the conceptualization of the disorder it became abundantly clear that the risk of 
developing SZ aggregated in family members, with an affected family member conveying 
considerably more risk as shown by twin and familial studies (Tandon et al., 2008b). These findings 
of course led to the interpretation of a genetic basis of disorders like SZ and hence heterogeneity 
explains the portion of variance liable for a disorder or illness accounted for by genetics (Tandon et 
al., 2008b). As epidemiological studies have progressed, SZ has gathered heritability estimates 
ranging from 60-80%, which are also influenced by environment (Hilker et al., 2018; Toulopoulou et 
al., 2019).  Since the discovery of such links, multiple study designs and approaches have been 
developed and used in research. Clinical genetic studies identify the extent to which genetic 
underpinnings contribute towards disorder development. Chromosomal and linkage studies allow 
interrogation of placeholders in the genome where relevant risk genes may reside, association studies 
aim to identify variant modification to disorder risk and lastly knock-out studies allow for specific 
brain processes to be studied via this genetic modification (Tandon et al., 2008b), albeit this suggests 
the readiness of an animal model for the disorder.  
 
The advent of molecular genetics saw linkage analysis studies emerge as the first DNA-based method 
aiming to discover genomic regions in affected extended or nuclear families and sibling pairs without 
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implication of specific allelic variants (Henriksen et al., 2017). These studies examine linkage in the 
form of co-segregation of genetic markers and predefined phenotypic traits whereby estimates of 
linkage between markers and the disease could be determined. This method is based on the physical 
linkage seen between sets of genomic loci on the same chromosome, which tend to be inherited 
together during meiosis (Henriksen et al., 2017). However, due to difficulties in replicability of 
linkage studies, it was determined that although SZ susceptibility loci were found harboring variants 
of importance, the loci themselves are not necessarily conferring risk (Badner and Gershon, 2002; 
Lewis et al., 2003; Ng et al., 2009). Hence this method proved impractical in power to address 
genomic loci with small effects and required cohorts of considerable size to address such issues 
(Risch and Merikangas, 1996).  
 
The next molecular technique that attempted broadening the picture of SZ etiology was candidate 
gene approaches. These approaches utilized a case-control study design to identify potential, 
candidate susceptibility genes for the disorder and eliminated the problems experienced with linkage 
in detecting genes with small effect alleles (Henriksen et al., 2017). The majority of candidate genes 
have been selected due to their position or functionality with the mostly commonly cited amongst 
those being neuroregulin 1 gene (NGR1) (Mostaid et al., 2017), dysbindin gene (DTNBP1) (Yuan et 
al., 2016), the dopamine receptor genes (DRD1 – DRD4) (Talkowski et al., 2007; Hall et al., 2015), 
disrupted in schizophrenia 1 gene (DISC1) (Niwa et al., 2016) and the catechol-O-methyl-transferase 
gene (COMT), to name a few (Lewandowski, 2007; Matsuzaka et al., 2017). However, despite 
thousands of candidate genes being investigated in these types of studies the results as a whole have 
been underwhelming in translation to a better pathophysiological understanding of the disorder 
(Gejman et al., 2011; Haraldsson et al., 2011).  
 
Perhaps the most suitable methodology for uncovering the genetic basis of SZ thus far has been that 
of association studies, like Genome-Wide Association Studies (GWAS) (Schizophrenia Working 
Group of the Psychiatric Genomics Consortium, 2014), however these studies have only reported 
around 25% heritability for SZ (Anttila et al., 2018). In these hypothesis-free studies, variation in 
gene sequences spanning the genome can be compared between different phenotypic groups to 
identify loci associated with a specific trait. However, this approach comes with interpretive 
difficulties (Frelinger, 2015). The following genes and associated variants linked to etio-pathogenic 
relevance in SZ are important candidates in uncovering genetic contributors, NGR1, DISC1, 
DTNBP1, DRD1 – DRD4 and COMT. Despite the identification of such associations, the etiology of 
SZ is known to be highly heterogenous and likely due to many genetic associations of small effect-
sizes (Owen et al., 2005) and as a result impedes researchers abilities to perfectly replicate all 
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findings. Despite the advent of GWAS and its genetic contributions, most hits have not been 
identified in coding regions of the genome (Schizophrenia Working Group of the Psychiatric 
Genomics Consortium, 2014), indicative of an epigenetic component in the disorder 
pathophysiology. 
 
The introduction of GWAS led study designs a priori of selected candidates, in a hypothesis-free 
manner allowing for interrogation of the whole genome in the hopes of identifying more informative 
genetic associations with disorder etiology. This unbiased approach uses the mapping of millions of 
single nucleotide polymorphisms (SNPs) facilitated by the International HapMap and Haplotype 
Reference Consortiums (1000 Genomes Projects), by which microarrays and chips facilitate scanning 
of said SNPs (International HapMap Consortium and others, 2003; Siva, 2008; Henriksen et al., 
2017). The premise of GWAS is linkage disequilibrium, where non-random association of alleles 
occur at two or more loci and in this has been hypothesized that frequently occurring specific allele 
variants in patients may be indicative of genetic associations. Genome-wide significance has been 
established in these studies in attempts to diminish the occurrence of Type I errors or false positives, 
with a stringency set to p <5x10-8  (Henriksen et al., 2017). To date SZ-focused GWAS have largely 
failed to provide consistent support for the findings outlined by linkage and candidate gene studies 
but rather have provided insight to hundreds of susceptibility loci and traits with genome-wide 
significance and have been substantiated in meta-analytic replication studies (Ripke et al., 2013; Shi 
et al., 2009; The Schizophrenia Psychiatric Genome-Wide Association Study Consortium, 2011; 
Xiao and Li, 2016). Additionally, the Major Histocompatibility Complex (MHC) locus on 
chromosome 6 has been found repeatedly in such GWAS with SZ-genetic associations, which 
indicates this locus as the strongest in terms of significance. Famously the SZ working group of the 
Psychiatric Genomics Consortium (PGC) identified 128 independent SZ associations spanning 108 
SZ risk loci, providing support for links between SZ, the dopaminergic system, and immune 
regulation (Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014). These 
GWAS findings also address issues that arose in other molecular genetic study approaches with the 
employment of massive consortia. Importantly GWAS has allowed for many novel SZ risk loci to be 
identified, each contributing in part to the observed heritability of the disorder.  
 
The above findings in common alleles were thought to only attribute to about 1-2% of the genetic 
risk of the disorder (Zhang and Malhotra, 2013a). However, it has been estimated that only ~5% of 
genetic risk variance explained by common risk loci passing significance (Corvin and Sullivan, 
2016). To date this common allele heritability is estimated to explain 25% of susceptibility for the 
disorder, however these risk loci fail to pass similar significance thresholds (Corvin and Sullivan, 
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2016). The shortcomings and limitations of GWAS are discussed further in context to this study 
below (section 1.11). The molecular genetic findings surrounding the polygenic nature of SZ have 
clearly indicated genetics as a strong risk factor for the disorder, however many of these approaches 
are accompanied by limitations and are based off of prior assumptions surrounding SZ transmission 
(Henriksen et al., 2017). Considering the clinical manifestation of SZ and its variability amongst 
patients, there is a clear indication of the need for incorporation of genetics into clinical 
conceptualization and diagnostics of SZ. As mentioned, the limitations of the current methodology 
leave much to be desired and the interrogation and interpretation of results need to be done so in a 
manner that eludes to the functional consequences and relevance to biological functioning of the 
individual (Sauer et al., 2007; McCarthy et al., 2014), which can be attained via a systems genetics 




As mentioned, environmental factors are known to interact with genetic variation in the etiology and 
manifestation of schizophrenia. These exposures include both biological and psychosocial risk factors 
from as early as antenatal and perinatal development periods through to childhood and adolescence 
and into early adulthood (Mäki et al., 2005). Links have been made between maternal infections and 
nutrient deficiency during the first and second trimester of pregnancy and an increased liability 
towards the development of SZ (Meyer et al., 2007; Penner and Brown, 2007). The exact 
neurobiological mechanism by which this risk is conferred is not clearly understood, however 
cytokines and aberrant immune responses to maternal infections have been seen to interfere with 
normal fetal brain development (Ashdown et al., 2006). Individuals having experienced childhood 
adversity are also at higher risk for development of the disorder (Schmitt et al., 2014). Socioeconomic 
stressors like urbanicity, migration, and socioeconomic status at birth were also found to increase risk 
towards SZ (Schmitt et al., 2014; Tandon et al., 2008b). Cannabis use during adolescence has also 
been linked to an increased risk for development of the disorder (Semple et al., 2005).  
 
Arguably the most relevant inheritance model when considering gene-environmental interactions, for 
SZ is the “omnigenic model” in proposing a broader view of the genetic contributions underlying 
complex disorders like such. In the conceptualization of this model, Boyle et al., (2017) concluded 
findings to an extremely large number of common causal variants with small effect-sizes widespread 
across the genome, genetic contributions to disease markedly occur in regions transcribed by active 
chromatin and lastly that many of the ‘larger effect’ variants are modestly enriched in specific genes 
or pathways directly influencing disease. Despite these findings, it was consensus that the variants 
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contributing the most disease heritability tended to be spread across the genome and not in proximity 
to known disease-specific functioning genes, suggesting that perhaps the surrounding or “peripheral” 
genes to those considered as “core” genes in disease were important for disease heritability (Boyle et 
al., 2017). To substantiate their hypothesis, observations regarding contribution towards heritability 
of a disorder indicated that cell regulatory networks are highly interconnected and gives credence to 
any expressed genes regulating functioning of so-called core genes. These networks thus likely 
encapsulate all levels of interactions among cellular molecules, transcriptional networks, post-
transcriptional modifications, protein-protein interactions and intercellular signaling (Peedicayil and 
Grayson, 2018). Newly developed molecular, technological and statistical methods over the last 
decade have sought to further uncover the genetic basis of SZ. Research efforts like the Human 
Genome Project brought much optimism in that determining the sequence of the entire genome would 




Epigenetic markers can be thought of as the molecular ties between external (environmental) and 
internal factors interacting to contribute to the clinical disorder manifestation. GWAS have made it 
abundantly clear that changes to DNA sequence are a crucial aspect of SZ disorder aetiology 
(Ovenden et al., 2018a), and the interplay between such alterations and the environment are mediated 
by epigenetic mechanisms. Epigenetics can be described as heritable change brought about in gene 
regulation and expression, exclusive of changes in DNA sequence (Bird, 2007). The umbrella term 
“epigenetic mechanisms” encapsulates those which regulate gene expression often leading to 
permanent changes that maintain stability throughout the lifetime of the organism and are potentially 
heritable (Goldberg et al., 2007; Portela and Esteller, 2010). These interactions result in differential 
clinical disorder phenotypes, however the mechanisms whereby these interactions take place are not 
fully understood. One such mechanism that has gained traction in literature though, is that of miRNA-
mediated regulation. 
 
Mechanisms as such are crucial in allowing for expression profiles which may adapt to a changing 
environment (Abdolmaleky, 2014). Regulatory mechanisms as such have been investigated in the 
genetic architecture of disorders and treatment response studies to a degree (Ovenden et al., 2017, 
2018a). Signatures of epigenetic regulation resonate heavily throughout neurodevelopment, 
furthermore research on epigenetic dysfunction has shown evident impact in brain growth, synaptic 
plasticity, learning, memory and circadian rhythm (Borrelli et al., 2008; Mehler, 2008; Pidsley et al., 
2010; Roth and Sweatt, 2009; Nakahata et al., 2007). This dysfunction has also understandably been 
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implicated in the development of psychiatric disorders like SZ (Ptak and Petronis, 2010). Growing 
evidence has shown links between regulatory variants, aberrant gene expression and NP disorders 
(Collins et al., 2010; Turner et al., 2016; Xiao et al., 2017; Yuen et al., 2016; Zhang and Lupski, 
2015).  
 
Maintaining transcriptional homeostasis is a fundamental regulatory mechanism for gene expression. 
Transcriptional homeostasis as described by Sallie (2004), is a proteins ability to modulate error 
incorporation (variability), with a subtle form of quality control seen exerted over protein synthesis 
(Sallie, 2004). This mechanism is fundamental to maintaining balance in cells. The regulation of 
RNA transcription and protein expression would be unsurprising in other roles like mediating 
immune escape and controlling cellular differentiation (Sallie, 2004). The following illustrates all 
factors in the system: (i) translated proteins interact with RNA polymerase; (ii) these interactions alter 
both polymerase processivity and fidelity; (iii) allowing wild-type protein or RNA polymerase 
interactions to be more avid and replicate alike RNAs more rapidly than mutant protein/RNA 
polymerase interactions (Sallie, 2004). Transcriptional dysregulation however, can be noted as any 
disruption/alteration or discontinuity in this process. In the context of this study, homeostasis can be 
viewed as the body’s natural ability to respond to external and internal stimuli that work in disruption 
of a homeostatic alignment to biological and molecular functioning.  
 
To date a sizeable amount of literature exists on the role of DNA methylation in psychiatric disorders 
(Teroganova et al., 2016). The clear and direct alterations seen by addition of methyl groups results 
in gene silencing with methylation identified in the psychopathology of many neuropsychiatric 
disorders like SZ as well as methylation target sites being identified for drug development (Denis et 
al., 2011; Grayson and Guidotti, 2013; Hendrich and Bird, 1998). Previous work has shown 
significant deficits in repressive DNA methylation affecting expression of the GAD1 gene in 
individuals afflicted by SZ (Huang and Akbarian, 2007). Further investigations observed 
hypermethylation of post-mortem brain samples, at the promoter region of the RELN gene of SZ 
individuals (Abdolmaleky et al., 2005; Tochigi et al., 2008). Less literature on miRNA-mediated 
regulation in neurodevelopmental disorder manifestation can be found. These ~22 nucleotide (nt) 
long, abundant regulatory RNAs have been shown to have crucial roles in maintaining central nervous 
system functioning like neural differentiation and cognitive functions (Aksoy-Aksel et al., 2014; Sun 
and Shi, 2015; Woldemichael and Mansuy, 2016). 
 
While epigenetic mechanisms have been identified to be involved in disorder pathogenesis the role 
of post-transcriptional mechanisms are not well understood (Du et al., 2019a). Such mechanisms like 
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those mediated by miRNAs have gained much traction in literature for their prevalent and global 
mechanism of action (Bartel, 2004; Du et al., 2019a; Mingardi et al., 2018). Widespread post-
transcriptional effects on hundreds of genes by these endogenous RNA molecules exposes significant 
potential in disentangling the genetic architecture of etiology and treatment response in complex 
disorders like SZ. This too can further be substantiated by the following discussed insight to 
regulatory and noncoding regions of the genome (section 1.13), which may help address the missing 
heritability that is observed following GWAS and other approaches.   
 
1.7. MicroRNA-mediated regulation  
 
The identification of the first miRNA was in 1991 when an unusual deletion of two small sequences 
in the 3’ untranslated region (3’-UTR) of the lin-14 messenger RNA (mRNA) in Caenorhabditis 
elegans was observed causing an accumulation of the protein (Wightman et al., 1991). No differences 
were observed in stability or functioning of the protein upon these deletions, suggesting post-
transcriptional repression by binding of the respective mRNA (Wightman et al., 1991; Thomas et al., 
2018). Since their initial discovery, multitudes of miRNAs have been identified, not only observed 
in worms, but in other animals and humans as well. These small, conserved regulatory mechanisms 
were observed to bind via complementary base pairing to target mRNAs and research focusing on 
them accelerated rapidly (Thomas et al., 2018). Proteins mediating miRNA synthesis were 
subsequently identified in parallel to elucidation of the RNA interface pathway, with the Dicer protein 
identified as the  generator of mature miRNAs via cleavage of double-stranded miRNA precursors 
(Hutvagner, 2001). The Drosha enzyme was later identified to generate said miRNA precursors from 
longer primary transcripts and Argonaute proteins (Ago1-4) were seen to directly bind to miRNAs to 
mediate their effects on mRNA targets (Lee et al., 2003; Liu, 2004; Meister et al., 2004). The role of 
these small regulatory molecules soon became apparent, with critical implications in the development 
and function of the central nervous system  (Thomas et al., 2018). Further identification of brain-
enriched miRNAs in mouse brain (Lagos-Quintana et al., 2002) and expression in mammalian 
neurons provided the basis for suspected roles in neurodevelopment (Krichevsky, 2003; Miska et al., 
2004). Early studies such as these provide evidence that miRNAs likely regulate brain development 
and neuronal functioning.  
 
This regulation of brain development and neuronal functioning is brought about by the binding of 
respective miRNAs to the 3’-UTR region of their correlated target mRNA transcripts. Pinnacle 
studies identified the significant roles of these small RNAs in neural biology – illustrated by 
conditional Dicer ablation, miRNA depletion was observed in both neuronal progenitors and mature 
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neurons and subsequent impaired differentiation, function and neurodegeneration (Cuellar et al., 
2008; Davis et al., 2008; De Pietri Tonelli et al., 2008; Kim et al., 2007; Schaefer et al., 2007). 
Positionally miRNA genes may lie within both intergenic spaces or introns/exons of protein coding 
genes (O’Carroll and Schaefer, 2013; Rodriguez, 2004). The binding of miRNAs to their targets does 
not necessitate perfect complementarity, nevertheless effects are mediated following site recognition 
as mRNA degradation or translational abnormalities (Thomas et al., 2018). The regulation of 
translation from mRNA to protein is mediated by miRNAs bound to a region that too has given insight 
to the effects of regulatory mechanisms. The binding of these small molecules to the 3’ UTR and the 
mechanism that is actioned is known to contribute to synaptic plasticity in the mature brain, a process 
frequently disrupted in disorders like SZ (Aksoy-Aksel et al., 2014). The first evidence of this 
regulatory impact on plasticity was shown with miRNA-134 localizing to the postsynaptic 
compartment and locally regulating translation of limk1 mRNA, which encodes a kinase with crucial 
implications for dendritic spine development in rats (Schratt et al., 2006). Importantly this study 
demonstrated how even a singular miRNA may have significant impacts on regulation and further, 
on neural circuitry.  
 
Famously, miRNA-137 was identified to have roles in regulation of pre- and post-synaptic signalling, 
neuronal maturation and various forms of synaptic plasticity (Thomas et al., 2018; Sakamoto and 
Crowley, 2018). Moreover it was found that miRNA-137 dysregulation was associated with 
intellectual disability and SZ, implying a critical role in human brain functioning (Thomas et al., 
2018). This miRNA is arguably the most well known in SZ research (Arakawa et al., 2019; Lett et 
al., 2013), with a GWAS revealing a novel SZ-associated SNP within the MIR137HG gene, along 
with another four loci known to harbour miRNA-137 binding sites (The Schizophrenia Psychiatric 
Genome-Wide Association Study Consortium, 2011). These findings were replicated by Kwon and 
associates (2013) and Ripke et al., (2013, 2014), with an additional SNP in MIR137HG (rs1702294) 
found to be second strongest in association to SZ by the latter research group (Kwon et al., 2013; 
Ripke et al., 2013; Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014). 
Notably both the identified SNPs minor alleles appeared to be protective against SZ (The 
Schizophrenia Psychiatric Genome-Wide Association Study Consortium, 2011; Schizophrenia 
Working Group of the Psychiatric Genomics Consortium, 2014). Further evidence was found in the 
DiGeorge 22q11.2 deletion, which is known to affect the key miRNA processing gene DGCR8 and 
patients having said deletion showed a 30-fold increase in risk of SZ (Stark et al., 2008). In addition 
to these findings, SNPs occurring in other miRNA genes (miRNA-206, 198, 30e) were associated 
with SZ across different ethnic groups (Feng et al., 2009; Hansen et al., 2007; Xu et al., 2010). Not 
only have SNPs in miRNAs been associated with SZ, SNPs within miRNA binding sites (i.e. the 3’-
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UTR) of SZ candidate genes were implicated in SZ risk when alteration to the binding site was 
resultant (Gong et al., 2013). 
 
Case-control studies have led to the identification of differential expression profiles of circulating 
miRNAs in NP disorders like SZ (Du et al., 2019a; Geekiyanage et al., 2012; Gururajan et al., 2016; 
Maffioletti et al., 2016). In a SZ case/control study, 18 miRNAs were identified with significant 
expression changes between the groups and suggested potential diagnostically relevant biomarker 
miRNAs for distinguishing those with SZ from those without  (Du et al., 2019b). The authors further 
suggested additional inquiry to the clinical relevance of such miRNA biomarker potential. The 
specificity of miRNA “hetero-silencing” determines regulatory impact across a vast number of genes 
(Bartel, 2004). In conjunction with the significant overlap observed in the genetic architecture of 
various NP disorders (both aetiology and ATR) it makes sense to further investigate the lengths to 
which this regulation influences the clinical manifestations that are seen (Calabrò et al., 2018; Cross-
Disorder Group of the Psychiatric Genomics Consortium et al., 2019a, 2013; McGregor et al., 2019; 
Smeland et al., 2019). The SZ-working group of the PGC have explored the role of miRNAs in SZ 
risk genes in relation to the discovery of 108 genomic loci previously and provided evidence of 
miRNA in the aetiology of SZ (Hauberg et al., 2016a; Schizophrenia Working Group of the 
Psychiatric Genomics Consortium, 2014). The role of miR-9-5p in particular was found to be 
implicated in functions of neurodevelopment and regulation of the dopamine D2 receptor density. 
Additionally, 43 mature miRNAs were uncovered in SZ-GWAS loci (Hauberg et al., 2016b). 
Although inconsistent association of this group of miRNAs with SZ was found, the nature of their 
mechanism of action highlights potential influence in other areas of the disorder – such as ATR. 
 
1.8.MiRNAs and pathways 
 
Upon validation of targets like those of miRNA-137, bioinformatic analyses have revealed many SZ 
relevant pathways, like that of axonal guidance and ephrin receptor signalling, synaptic long-term 
potentiation (LTP) and protein kinase A (PKA) signalling (Wright et al., 2013). Although little to 
date is known about these specific pathways and others in SZ, the identification and evaluation of 
pathway-specific gene sets may allow for insight to consequential dysregulation of said pathways by 
miRNAs and how this confers risk (Wright et al., 2013). Alterations in activity patterns in neural 
circuitry supporting mental processing have shown a need for understanding the corresponding 
underlying biological pathways for complex conditions like SZ (Willsey et al., 2018). Considering 
miRNA-mediated regulation of gene expression, an aggregation of said regulated genes likely interact 
within biological pathways or at gene-network levels (Guo et al., 2010) and may offer an explanation 
Stellenbosch University https://scholar.sun.ac.za
 15 
for missing heritability in NP disorders and associated traits. The findings supporting the “omnigenic 
model” of inheritance (section 1.1) too provides credence for miRNA-mediated regulation underlying 
complex disorders like SZ and associated traits. Transcription factors (TFs) and miRNAs may interact 
in one of two ways; either by reciprocally regulating one another forming feedback loops, or by both 
regulating their respective targets forming feed-forward-loops (FFLs). In an exploratory miRNA-TF 
mediated regulatory network analysis, FFLs as well as mutual feedback loops were identified in SZ 
(Guo et al., 2010). Well-documented candidate genes like DISC1 are linked to SZ relevant pathways 
including the Wnt signalling pathway via inhibition of GSK3ß (Mao et al., 2009). Given how little is 
known about miRNA-mediated regulation in pathways relating to complex disorders and ATR, this 
is a potential avenue for  interrogation of regulatory mechanisms, via their associated targets and 
subsequent pathway involvement. Therefore, potential insight to the consequence of dysregulation of 
miRNA-mediated regulation is also a possibility.  
 
1.9.Treatment and response 
 
The utilization of antipsychotic (AP) treatment for disorders like SZ, stands alone as the main method 
for management of the associated symptoms, where a single (monotherapy) or a combination 
(polypharmacy) of AP drugs can be used (Faries et al., 2005). One of the many challenges facing 
antipsychotic utilization is the limitation in alleviation of all pathological dimensions of the disorder 
for which treatment is necessary (i.e. negative, positive, and general/cognitive symptomology 
alleviation). Polypharmacy is usually as a last resort once all other monotherapy drugs have been 
exhausted in efforts to circumvent symptoms (Faries et al., 2005). Typically, the use of a singular 
antipsychotic is preferred when treating disorders like SZ, enabling the clinician to somewhat 
accurately monitor the patients response including avoidance of potential adverse side effects (Miller 
and Craig, 2002). The advent of AP drugs saw two classes of antipsychotics emerge; namely first-
generation (FGA), and second-generation (SGA) or typical and atypical antipsychotics, respectively 
– whereby typical antipsychotics are often associated with extrapyramidal signs/symptoms (EPS) 
induced in an adverse response (Miller and Craig, 2002). Both classes of antipsychotics work to 
resolve positive symptoms associated with SZ, like delusions, hallucinations, and thought 
disorganization, however SGAs were considered by practitioners to be more effective with broader 
range of efficacy regarding negative and cognitive symptom domains as well (Tandon et al., 2008a). 
Non-response to medication is seen in ~20-30% of patients and only around half show favourable 
symptom improvement (Ackenheil and Weber, 2004; van Os and Kapur, 2009; Allen and Bishop, 
2019).  The comparative efficiency between these two classes of AP drugs is however highly debated, 
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though one fact remains despite the armamentarium of drugs available, the treatment of SZ and 
complete alleviation of symptoms is still unsatisfactory.  
 
1.10. Adverse drug response 
 
To date no AP agent has proved effective at alleviating symptomology across all domains, with 
inaccurate dosage decisions regarding prescription and henceforth treatment, are largely handled on 
a ‘trial-and-error’ basis (Tandon et al., 2008a). It is widely accepted however that SGAs have a lower 
inclination to induce EPS versus that of FGAs (Tandon and Jibson, 2002), however the SGAs have 
been associated with adverse metabolic effects (Tandon et al., 2008a). The risk of developing adverse 
drug reactions (ADRs) during treatment naturally introduces issues with patient compliancy. 
Metabolic side effects not only diminish the patients overall health outcomes, they can lead to serious 
risks like ischemic heart disease via antipsychotic-induced weight gain, dyslipidaemia and diabetes 
mellitus (Newcomer, 2005; Franciosi et al., 2005; Maciukiewicz et al., 2019). Accompanying these 
adverse metabolic effects are EPS, which are further subdivided into early-acute and late-onset EPS. 
Early-acute symptoms manifest at the beginning of treatment, or in alteration of treatment dosage and 
include akathisia (restlessness and pacing), acute dystonia (prolonged abnormal postures and muscle 
spasm) and parkinsonism (tremors, muscle rigidity and bradykinesia) (Mas et al., 2016). Given the 
nature of EPS, this class of adverse effects are heavily debilitating to the individual, stigmatizing and 
require additional pharmacotherapy to combat their occurrence (Divac et al., 2014). However very 
few studies into the proposed differences in FGA and SGA efficiencies have been done, of which the 
large-scale Clinical Antipsychotic Trials of Intervention Effects (CATIE) (Lieberman et al., 2005) 
and the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia (CUtLASS) (Lewis et al., 
2006b) studies found no significant observations supporting these claims. These studies did however 
provide evidence of clozapine having high levels of success in the treatment of refractory-SZ in 
particular (Lewis et al., 2006a). In combination with other measures, AP treatment has a significant 
impact on the course of illness (Figure 1.5) and thus optimal use, efficiency and avoidance of ADRs 















Figure 1.5 Antipsychotic treatment as key factor in schizophrenia recovery outcome (Tandon et al., 
2008a). Reprinted with permission from Elsevier 
 
1.11. Antipsychotic Treatment Response (ATR) 
 
Interindividual variation is seen in drug response amongst patients indicating this as complex trait 
within SZ, in which the variation in genetic makeup relating to drug metabolism and 
neurotransmission, amongst other pathways, are factors (Blanc et al., 2010; Klein and Zanger, 2013; 
Ni et al., 2013). Investigation into patient’s metabolic status evidence suggests a substantial role for 
genetic factors underlying this between-patient response variation. This was further substantiated by 
identified dopamine and serotonin receptor gene variants repeatedly associated with response 
phenotypes (Arranz and De Leon, 2007). Although methods for estimating patient response to 
antipsychotics are not standardized, the general approach is to use scales of symptom severity, like 
the Positive and Negative Syndrome Scale (PANSS) discussed previously (section 1.3) and to 
measure change in the respective symptom scale scores as indicative of treatment response for each 
symptom domain. Antipsychotic drug trials have largely utilized cutoff values in scales like the 
PANSS to define response, typically measured with baseline and post-treatment scores of these rating 
scales (Leucht et al., 2007). The definition of treatment outcomes has also been a challenge in 
accurately reporting ATR, with the ultimate goal of treatment aiming to maintain a state of remission 
devoid of relapse. The Remission in SZ-working group convened to develop criteria of remission 
states to accurately assess long term health outcomes for schizophrenia patients, enabling cross-study 
comparisons (Andreasen et al., 2005). These criteria state a low-mild symptom severity, where said 
symptoms do not impede a patients functionality and behavior (Frank et al., 1991).  
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Attempts at uncovering predictors of treatment response have long been a subject of research 
surrounding mental disorders like SZ, especially with the advent of AP treatment in the hopes of 
maintaining long-term outcomes like remission. Patients with poor insight towards their disorder 
underestimate or deny symptoms and the extent to which they are affected by the disorder and 
unsurprisingly are associated with reduced compliance and subsequent poor outcome. Importantly a 
factor like insight may be modified by pharmacological interventions and serves to predict potential 
relapse (Emsley et al., 2008). Another determinant of treatment response is duration of untreated 
psychosis (DUP), which displays potential for modification by pharmacological intervention. The 
shortening of the DUP period allows for improved treatment outcomes and can be seen inversely 
related to one another, where shorter DUP essentially equals a greater treatment outcome on the path 
to remission (Marshall et al., 2005; Perkins et al., 2005). As mentioned compliancy issues in treatment 
naturally impede treatment outcome, with non-adherence in patients resulting in a significantly higher 
risk for relapse (Robinson et al., 2004). However, issues surrounding non-adherence have been 
largely combatted with the introduction of long-acting injectables (LAIs), whereby other predictors, 
like early response have emerged. Asher-Svanum et al., (2011) evaluated early response to LAIs in 
attempt to find any association with improved overall response, qualifying as 40% improvement in 
symptomology (Ascher-Svanum et al., 2011). Early responders were defined as 30% improvement 
in PANSS scores by the fourth week and were predicted to experience significantly better clinical 
and functional outcomes for LAI overall response later. Lastly, the ability to identify patients failing 
to respond to initial treatment has proved to be a crucial predictor for patient health outcomes. The 
option of an alternative antipsychotic and earlier intervention can hence be considered in an attempt 
to prevent ensuing morbidity as a consequence of nonresponse (Chiliza et al., 2015a). It has been 
seen even in cases of standardized treatment that only a small percentage (23%) of patients responded 
to a secondary AP upon failure to respond to initial treatment. However more promising was the 
introduction of clozapine which saw a much larger group of patients (77%) with robust response, 
despite two failed treatment trials (Agid et al., 2007). It has therefore been proposed that an initial 
nonresponse can be predictive of subsequent nonresponse to another AP, other than clozapine 
(Remington et al., 2013).  
 
Discrepancies in treatment response and interindividual variability can be attributed to the genetic 
constitution of an individual – although it has been shown that even this variability can only account 
for small interindividual differences, indicative of some non-genetic mechanisms acting on treatment 
response (Swathy et al., 2017; Ventola, 2013). High heritability and multifaceted genetic inheritance 
patterns of disorders like SZ, suggest that the interpretation of both common and rare variants from 
otherwise ‘unexplored’ genes (i.e. those not targeted in candidate gene studies) may reveal biological 
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mechanisms that are key in understanding disorder pathophysiology from ATR (Cross-Disorder 
Group of the Psychiatric Genomics Consortium and others, 2013). The identification of ATR as a 
complex trait then suggests that a considerable number of variants exist and ultimately interact to 
bring about these individual treatment response phenotypes that are observed (Ovenden et al., 2017).  
 
Efficacy issues of antipsychotics  naturally present compliancy issues for patients, which are further 
complicated by treatment strategy and variety, requiring optimization according to phase and severity 
of the disorder (Miyamoto et al., 2005). Primary focus on interindividual variation in drug efficacy 
has led to the development of pharmacogenetic strategies in the hopes of further developing 
pharmacogenetically-informed individualization of treatment. In addition, these strategies will aid in 
uncovering the potential underlying non-genetic mechanisms linking varied clinical manifestations 
and potentially explaining observed missing heritability in traits regarding disorders like SZ 
(Malhotra et al., 2012b). Considering the abundance of GWAS results available, investigation into 
noncoding regions of the genome is plausible, especially when noting how many results are reported 
occurring within these regions and whereby the associated SNPs are enriched for, or implicated in 
regulation (Maurano et al., 2012; Schaub et al., 2012). Pharmacogenomics has set out to uncover 
potential variants that may be interacting to bring about treatment response mechanisms, while 
considering a multi-directional relationship with common and rare genetic factors, environmental 
factors and gene-environment interactions like epigenetics (Manolio et al., 2009; Majchrzak-Celińska 
and Baer-Dubowska, 2017).  
 
1.12. MiRNAs in ATR 
 
Traction in literature over the last decade has led to investigation of miRNA involvement in NP 
disorders and various aspects of disorder pathophysiology like those discussed above, however 
investigation of their involvement in ATR has been limited. The regulatory effects of miRNAs are 
widespread, with the ability to regulate 20-30% of human genes (Lewis et al., 2005), highlighting 
potential roles in more than one avenue of disorder pathophysiology, with potential pathway 
disruption interacting in ATR mechanisms as discussed (section 1.11). Moreover the ability of 
miRNAs to target and therefore regulate, regulatory genes (i.e. DNMT genes in DNA methylation) 
introduces a potential regulatory cascade to be considered. 
 
Importantly, Shi and colleagues illustrated both miRNA-9 and miRNA-326 mediated regulation of 
DRD2 expression (Shi et al., 2014). The authors found that miRNA-326 overexpression reduced 
DRD2 mRNA and DRD2 receptor synthesis, however when observing antisense miRNA-326 and 
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miRNA-9, DRD2 protein abundance was increased suggestive of endogenous repression by both 
miRNAs. Lastly, the variant rs1130354 residing within the DRD2 3’-UTR was seen to interfere with 
miRNA-326 mediated repression of DRD2 expression. This study highlights the ability of miRNAs 
to regulate dopaminergic signalling. Considering that AP drugs directly interact with the 
dopaminergic system this provides substantial grounds to investigate miRNAs for potential influence 
in ATR. Another study shows an association between the down-regulation of miRNA-181b 
expression and improvement in negative symptoms of schizophrenia in a treatment naïve case/control 
cohort, constituting 20 SZ patients and 20 age-and-gender-matched controls. The expression of 
miRNA-181b, amongst others (miRNA-30e, miRNA-34a, and miRNA-7), was significantly higher 
in patients than in the normal control group (Song et al., 2014). A comparison was also made between 
pre- and post-treatment of the patient group, where miRNA-181b was found to be significantly 
downregulated, however four different antipsychotics were under examination in this study and so it 
cannot be determined which drug(s) were responsible for the observed changes in miRNA expression 
levels. Furthermore, studies examining expression of miRNAs in relation to ATR have not yet 
determined the potential roles that miRNAs may have in altering such responses, meaning 
characterization in a pathway-based, systems genetics approach may provide additional insights. 
 
1.13. GWAS in pharmacogenomics 
 
It was widely assumed that the utilization of GWAS upon its introduction a decade prior would unveil 
the genetic basis of complex disorders in their entirety, including implicated traits like ATR. It has 
become apparent via these study designs however, that casual factors may be more difficult to identify 
than originally thought and these shortcomings have given credence to different hypotheses of the 
genetic architecture of NP disorders like SZ and associated ATR as described above (section 1.11) 
(Gershon et al., 2011). Variants identified from disorder risk and drug target genes may have 
consequential impact as predictive markers on the individual level for predisposed risk and ATR 
(Kaur et al., 2014). Pharmacogenomics in this sense can be seen as a natural progression from the 
large-scale GWAS whereby the potential of variants to manipulate clinical symptoms and treatment 
response mechanisms has been identified (Kaur et al., 2014). The attempts at elucidation of genetic 
predictors of ATR has resulted in >500 pharmacogenetic publications examining the role of drug-
metabolizing enzymes, neurotransmitter receptors, transporters and signalling molecules (Grossman 
et al., 2008; Gupta et al., 2013; Need et al., 2009; Paddock et al., 2007; Perlis et al., 2009, 2007; Zandi 
and Judy, 2010a), however, the exact mechanisms underlying the observed variance in ATR remain 




This strategy of identification of genetic associations is achieved by genotyping markers, which when 
chosen effectively tag nearby common genetic variants, covering the entire genome with the premise 
of detecting associations between marker identified alleles and traits in samples of a given cohort 
(Gershon et al., 2011; Visscher et al., 2017). The detection of associations for GWAS to 
pharmacogenetics however proves difficult in terms of statistical power that is incurred when 
genotyping hundreds of thousands of small effect size SNPs (Cichon et al., 2009). This introduced 
the need of very large cohorts, to match the numerous amount of SNPs genotyped to effectively 
combine the considered effects of each SNP and lessen the burden of multiple testing (Zeng et al., 
2015). GWAS chips have been developed with markers using the “common disease, common 
variant” basis as a working hypothesis, however these associations have failed to explain a substantial 
bulk of common disease inheritance, with limited clinical value  (Gershon et al., 2011) and hence see 
research leaning towards alternate working hypotheses to meet these aims.  
 
Currently GWAS has identified an abundance of genetic correlates and risk loci associated with 
commonly occurring NP disorders. Results from GWAS have been reported for an abundance of 
complex traits concerning major NP disorders like SZ, with results to date having likely revealed 
>200 SZ risk loci (Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014; 
Ripke et al., 2011, 2013; Yu et al., 2018; Cross-Disorder Group of the Psychiatric Genomics 
Consortium et al., 2019). Despite these promising results and polygenic inheritance that too can 
account for some portion of this missing heritability (International Schizophrenia Consortium, 2009), 
further interrogation of these results are required to uncover attribution to the total missing heritability 
observed. While the main focus of GWAS has been uncovering disorder etiology and causal factors, 
an important contribution to the management of NP disorders. Treatment response has often been 
overlooked. Multifactorial traits interact with treatment efficacy and pharmacogenomics has moved 
in the direction of unravelling genetic architecture from disorder aetiology, associated traits like 
treatment response. These approaches now aim to contribute towards the observed ‘missing 
heritability’ component that may be underlying aspects of ATR in complex disorders (Ovenden et 
al., 2018b).  
 
Given the limited clinical utility of most GWAS results, pharmacogenetic/genomic approaches were 
designed to disentangle disorder etiology from ATR, with the hopes of identifying reliable and 
clinically meaningful predictors of treatment response (Malhotra et al., 2012c). The terms 
pharmacogenetic and pharmacogenomic are often used interchangeably, although some have denoted 
the -genetic aspect to referring to singular genes under study versus the whole genome implied by -
genomic (Goldstein et al., 2003). In its entirety it is the relation of heritable variation to interindividual 
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variation in drug response. Pharmacogenomic studies have great appeal when considering 
heterogeneity and prognostic uncertainty seen in most NP disorders, offering steps towards 
individually tailored treatment for ATR. However, many pharmacogenetic studies are using a 
candidate gene approach, the majority of which are centred around receptor pharmacology of the 
psychotropic agent (Arranz and De Leon, 2007; Fleeman et al., 2011; Malhotra et al., 2012c).  
 
The roles of these genes can be further divided into pharmacokinetic and pharmacodynamic, where 
the former refers to the processes involved in drug metabolism and the latter to interactions between 
the drug, transporters and target molecule(s) (Zandi and Judy, 2010b). Pharmacokinetic studies are 
supported by identification of multiple functional variants with well characterized effects on drug 
metabolism, for example the >100 SNPs in the gene for the cytochrome P450 2D6 enzyme that have 
been associated with numerous drugs and metabolizer phenotypes (Ingelman-Sundberg, 2005; Ito et 
al., 2018). Many of these variants produce non-functional or reduced-function enzymes and led to the 
classification of four CYP2D6  phenotypes of enzymatic activity in drug metabolism; namely poor, 
intermediate, extensive and ultra-rapid metabolizers (Malhotra et al., 2012c). Although these 
classifications have been made, there is little evidence to merit the relationship between 
pharmacokinetic variation and drug dosage, however in prevention of ADRs some may advise on 
dosing according to CYP450 genotype (de Leon et al., 2006). Upon discovery of clozapine’s efficacy 
in treatment, many pharmacodynamic studies have investigated the interaction between this agent 
and the dopaminergic and serotonergic receptor systems (Arranz et al., 2011). The targeting of these 
systems has proved crucial for mediation of antipsychotic effect, with an association between the 
dopamine D4 receptor mediating efficacy of clozapine in SZ-patients otherwise deemed refractory 
(Zhao et al., 2005), alongside association of variation in the 5-HT2A receptor with clozapine treatment 
outcome (Arranz et al., 1995; Yu et al., 2001). These studies have provided much insight to the 
plethora of potential mechanisms of antipsychotics in treatment response, yet there has not been a 
distinct improvement in overall ATR thus far.  
 
Given the best efforts of multiple GWAS for many complex disorders, even outputs that are 
seemingly notable (i.e. identification of 108 independent genomic SZ risk loci with genome-wide 
significance) fall short in explanation of the causality, etiology and treatment outcomes 
(Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014). Interestingly some 
SZ risk loci identified in GWAS were found to be over-represented in active regulatory regions in 
the brain and also appeared enriched in genes regarding postsynaptic density, postsynaptic membrane, 
dendritic spine, axon and voltage-gated calcium channel pathways (Gusev et al., 2014; Roussos et 
al., 2014; Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014). Alongside 
Stellenbosch University https://scholar.sun.ac.za
 23 
the lack of improvement in ATR despite pharmacogenomic studies, alternative systems genetics, 
hypothesis-free approaches may lead to the answers that were not identified using these prior 
approaches. GWAS have divulged a wide spectrum of common variation, both in coding and non-
coding regions, with the latter found associated with disorder phenotype and consequential regulatory 
impact (Liou et al., 2012; Clark et al., 2013). The underlying pathophysiology of NP disorders like 
SZ may also be resultant of an interplay between both genetic and environmental factors. Therefore 
predictors of disorder etiology can potentially be uncovered when investigating individual genotypes 
in combination with respective environmental stressors (Roth et al., 2009).  
 
With the above knowledge gap identified and the clear potential for regulatory influence in SZ, I 
hence decided to investigate further this role that miRNAs may facilitate in the manifestation of 
differing ATR outcomes. The lack of research surrounding associated traits like ATR and heavy 

























1.14. Current study 
 
1.15. Aim and objectives 
 
This study aims to characterize the role of miRNA-mediated regulation of genes in the aetiology of 
antipsychotic treatment response, in a South African FES cohort. 
 
The specific objectives by which the aim will be achieved are as follows: 
 
1. Candidate gene approach  
Characterization of variation (novel and previously described) within candidate regulatory genes 
from the Taqman Human DNA methylation and transcriptional repression microarray (Applied 
Biosystems, California, USA). 
a. Identify variants by literature search, online databases for population-specific variation, 
eQTL databases and available whole exome sequencing for 11 MA FES patients. 
b. Identify SNPs which create or abolish miRNA regulatory sites using in silico tools. 
c. Prioritize variants for investigation using in silico bioinformatic tools. 
 
2. miRNA-target approach  
Characterize miRNA binding sites/target genes utilizing in silico analyses, for 43 mature miRNAs as 
identified by Hauberg et al., (2016).   
a. Identify gene targets for the identified miRNAs using gene ontology and biological 
pathway-based approaches. 
b. Identify variants annotated by known regulatory elements (TFBS and miRNA target sites) 
c. Correlate in silico predicted miRNA effects with online and available expression 
databases. 
 
3. Impact of identified SNPs and gene targets in the context of miRNA-mediated regulation 
and antipsychotic treatment response 
Investigate whether the prioritized miRNA-mediated SNPs/genes are associated with antipsychotic 
treatment outcomes in the SA FES cohort.  
a. Perform linear and/or logistic and mixed-effect regression analyses to identify 
associations of variants with antipsychotic treatment outcome as defined by a change in 
PANSS scores over time. 
b. Perform pathway analyses to identify potential miRNA-mediated regulatory impact in a 
systems genetics approach.  
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2. METHODS AND MATERIALS 
 































Figure 2.1 Proposed strategy outline of current study; M1: method 1; M2: method 2. 
 
2.1. Cohort demographics  
 
A previously recruited and described cohort of unrelated South African (SA) first episode 
schizophrenia (FES) patients was utilized (Drogemöller et al., 2014a; Chiliza et al., 2015b). The 
miRNA-mediated 
regulation and ATR
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predicted regulatory impact 
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cohort comprised of 103 previously drug-naïve patients, including 82 individuals of South African 
Mixed-Ancestry, 13 Xhosa, and eight Caucasian individuals. These individuals were represented by 
27 females and 76 males with a mean age of 24 years (standard deviation (SD): ± 6.71 years). Patients 
were recruited from Stikland Hospital. Both written and verbal consent was obtained from the patients 
or their respective caregivers where applicable. Clinical assessments were performed at nine different 
time intervals; fortnightly for the duration of 6 weeks, and then every three months thereafter 
(Drogemöller et al., 2014b). During assessments ongoing patients received an injectable first-
generation antipsychotic (FGA), i.e. Flupenthixol Decanoate (Fluanxol®, Lundbeck, Copenhagen, 
Denmark), bi-weekly over a period of 12 months. All clinical data, inclusive of PANSS scores, was 
obtained as well as the appropriate demographic information (age, gender, ethnicity). Additionally, 
the 103 patients were further stratified based on treatment-response outcome groups represented by 
nine individuals experiencing treatment refractoriness, 16 having relapsed, and 66 said to have 
experienced extrapyramidal adverse events (EPSAE) during the duration of treatment. 
 
2.2. Inclusion and exclusion criteria 
 
At the time of recruitment individuals were diagnosed using the fourth edition of the Diagnostic and 
Statistical Manual of Mental Diseases (DSM-IV) (APA, 1994) for schizophreniform disorder, 
schizoaffective disorder, or schizophrenia, having not been exposed to antipsychotic treatment for a 
maximum of a 4 week period during their lifetimes (Chiliza et al., 2015b). Inclusion criteria was 
based on the patient’s completion of three months of treatment with no relapse occurrence. Relapse 
were defined as a 25% increase in PANSS total scores, an increase of 10 points when PANSS total 
is less than 40, or clinical deterioration (CGI change score of six or seven). Individuals were excluded 
based on current substance abuse usage, previous treatment by long-acting injectable 




Blood samples were taken and DNA extracted for genotyping. Genotyped data was made available 
for the entire cohort, attained using the Illumina HumanOmniExpressExome BeadChip (Illumina, 
California, USA), for ~1 million SNPs. Resultant genotyped SNPs were used for analyses. The 
inclusion of ancestry informative markers (AIMs) for correction of population stratification was made 
due to the nature of the patient ethnicity groupings (Daya et al., 2013). Hence correction for 
population stratification is necessary. Genotyping for 100 AIMs previously designed for the South 





Ethical approval was obtained from the Health Research Ethics Committee, Faculty of Medicine and 
Health Sciences, Stellenbosch University (N06/08/148). 
 
2.5.MiRNA mediated regulation and ATR 
2.5.1.  (M1) Candidate gene approach 
 
In the hopes of providing greater insight of the underlying mechanisms influencing ATR in SZ, 
miRNA-mediated gene regulation was investigated in this study. A novel bioinformatic pipeline was 
utilized to identify genetic variants with known predicted effects pertaining to miRNA target and 
binding sites. This study design included a candidate gene approach (M1) and a hypothesis-free 
miRNA-target approach (M2). The candidate gene approach was based on previous work identifying 
the potential role of regulatory genes in ATR using a methylation and transcriptional repression 
microarray (O’Connell et al., 2019). However, considering all genes are subject to regulation by 
regulatory mechanisms, regulatory genes are no exception with regulatory influence from 
mechanisms like those mediated by miRNAs. The results of M1 will be further investigated via 
statistical association analyses and bioinformatic pathway analyses. The M2 results will be 
investigated via enrichment analyses and compared to the aforementioned as validation. The 
bioinformatic approach to be run in parallel for both approaches are outlined in Figure 2.2 below. All 











































Figure 2.2 Summary of bioinformatic pipeline flow used in this chapter, the results generated in the 
outcome will be further processed by Association Analyses and pathway interaction investigation 
respectively.  
 
2.5.2 Candidate gene selection 
 
Candidate genes were chosen from those described on the microarray aforementioned (appendix, 
Supplementary Table 1), in subsequent prioritization steps. The gene set enrichment analyses tool 
Enrichr (Chen et al., 2013; Kuleshov et al., 2016), was employed to assess the relevance of these 
genes in terms of predicted miRNA gene targets, as well as biological and molecular 
processes/functions relating to regulatory mechanisms, as well as any previously reported 
associations to SZ and related implicated neurological processes or previously described neurological 
impairments. Briefly, eight databases were chosen in relation to genes identified as miRNA gene 
targets, those with pre-identified implications in neurological processes and those relating to 
translation or transcription in any way. The candidate genes that were selected had to occur across 
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2.5.3 Variant prioritization 
 
Variants were identified within the selected candidate genes using PolymiRTs (Bhattacharya et al., 
2014) and were prioritized based on a prediction to interfere with miRNA-binding sites. All variants 
within these genes were considered for further analyses. A literature search was also performed to 
identify any known or commonly occurring variants which were included for comparative analysis 
with those already identified by PolymiRTs. The following key words/phrases were used in a manual 
search (April – May 2018) across PubMed (https://www.ncbi.nlm.nih.gov/pubmed/advanced) and 
Google Scholar (https://scholar.google.co.za) respectively; schizophrenia, pharmacogenetics, 
antipsychotic treatment response, miRNA-mediated regulation, signaling pathways.  
 
All relevant variants in the First-Episode Schizophrenic (FES) cohort’s SNP data were extracted 
using PLINK v1.90 (http://pngu.mgh.harvard.edu/purcell/plink). The FES data is described below. 
 
2.5.4. Bioinformatic analyses  
 
Predicted effects annotated by PolymiRTs were determined for the identified FES SNPs. Predicted 
functional and regulatory impacts of the variants chosen for further statistical and association analyses 
were performed using the online tool RegulomeDB for known and predicted regulatory elements 
in the intergenic regions of the human genome (Boyle et al., 2012). The predicted regulatory DNA 
elements include regions of DNAse hypersensitivity, transcription factor binding sites (TFBS), and 
promotor regions that have been biochemically characterized to regulate transcription. This tool 
sources data amongst public datasets from GEO (Barrett et al., 2012), the ENCODE project (Davis 
et al., 2018) and published literature. Next the tool rSNPBase (Guo et al., 2014a) was used to annotate 
the SNPs regulatory capacity with reference to experimentally supported regulatory elements (Guo 
et al., 2014a). rSNPBase focuses on regulatory SNPs (rSNPs) involved in various regulation types, 
including proximal and distal transcriptional regulation and post-transcriptional regulation, within the 
input genes. Spatio-temporal labels and experimental eQTL labels for SNPs are also provided. Allelic 
frequencies were investigated comparatively to Ensembl minor allele frequencies of the African, 
European, South Asian and East Asian populations. Genotypes and frequencies for the respective 
variants were also determined in the FES cohort, and compared to the frequencies within 1000 






2.5.5. Association analyses with ATR 
 
The identified variants that presented with a MAF 0.05 were used in the association analyses. 
Association analyses were performed in R (R Core Team, 2018) using the R packages lme4 (Bates et 
al., 2015) and lmerTest (Kuznetsova et al., 2017). Linear mixed-effects models were used for the 
investigation of the effect of genetic variants on change in PANSS scores for each respective subscale 
(positive, negative and general) and total over the 12-month period. Adjustments were made for age, 
gender, proportion ancestry (using AIMs markers) and baseline PANSS scores. This study is only 
concerning cases and hence associations calculated for respective variants and treatment outcomes. 
Indicators of treatment response are given as percent changes, observed for the respective symptom 
domain (PANSS over time). An observed positive change (percentage change values more than 
zero) is indicative of worsened ATR and negative (percentage change values less than zero) changes 
indicative of an improved treatment outcome over time.  
 
Both a genotypic and an additive mode of inheritance were investigated, with the inclusion of a 
genotypic model to account for potential heterozygous advantage, whereby selective preference for 
a heterozygous phenotype of higher fitness can occur (Charlesworth and Willis, 2009; Penn et al., 
2002). Bonferroni correction was used to correct for multiple testing. This resulted in a threshold 
value of p  1.04 x 10-3 (0.05 / (4 tests x 6 SNPs).  
 
2.5.6. Bioinformatic pathway analysis 
 
The identification of variants significantly associated with antipsychotic treatment outcomes, allowed 
for investigation of pathway and network interactions. These interactions may highlight underlying 
miRNA-mediated regulatory mechanisms interacting in a system potentially responsible for the 
manifestation of interindividual treatment response. The bioinformatic tool NetworkAnalyst (Xia et 
al., 2014, 2013b, 2013a; Zhou et al., 2019) was used for visual analytics for gene expression profiling 
and interrogation of network processes of interest. NetworkAnalyst (available at: 
https://www.networkanalyst.ca) was used to interrogate pathways in relation to gene-miRNA 
interactions and transcription factor-miRNA coregulatory network interactions. The NetworkAnalyst 
tool can be used to perform meta-analyses of gene lists or gene expression datasets labeled with 
multiple metadata parameters, or finally of multiple independent gene expression datasets. The data 
integration is achieved via robust statistical procedures and visual output to be explored within 




The four relevant ATR associated genes; SAP18, HDAC2, HDAC4, and HDAC5 were used as the 
gene list input for the meta-analysis and network visualization. During the analyses, summary-level 
data (P-values, fold changes (FCs) or effect sizes) is made available for user download as well, it is 
extracted and integrated to identify genes that are significantly altered in expression based on the 
overall evidence. The given input genes/drugs/chemicals are denoted as nodes, with edges classifying 
interactions between given nodes. Subnetworks are created as sets of connected nodes and edges. The 
p-value of a module is determined solely on network connectivity and gives an indication of how 
significant the connections within a defined module are. The edges within a module are denoted 
internal and edges connecting nodes of a module with the rest of the graph denoted external. 
Generally, the null hypothesis of the test states there is no difference between the number or internal 
and external connections to a given node in the module. The p-value is therefore calculated using a 
Wilcoxon rank-sum test (Wilcoxon, 1945) of the internal and external degrees. Selected genes here 
are presented within PPI networks. In the absence of gene expression data only a singular analysis 
can be performed as outlined in the workflow below (Figure 2.3). For the purpose of this study and 
given the nature of the predetermined microarray from which these genes were initially selected from, 























2.6. (M2) MiRNA-target approach  
 
2.6.1. MiRNA gene target identification  
 
The gene targets for 43 mature miRNAs (appendix Table 2) were identified using the online 
predictive tool PolymiRTS (Bhattacharya et al., 2014), the database of DNA variation occurring in 
miRNA seed regions and target sites, with predicted implications for miRNA-miRNA interaction and 
hence miRNA-mediated gene expression (Bhattacharya et al., 2014). The database can predict 
targeted genes of miRNAs of interest.  
 
2.6.2. miRNA target gene variant prioritization 
 
The bioinformatic tool, rVarBase (http://rv.psych.ac.cn), a database for regulatory features of human 
variants with regulatory features in three fields: chromatin state of the region surrounding variant, 
regulatory elements overlapped with variant, and variant's potential target genes (Guo et al., 2016), 
was used for the target gene variants to be prioritized. A literature search was also performed to ensure 
that any known or commonly occurring variants were included for comparative analysis to those 
identified by rVarBase. The same key words/phrases as described above, were used in searches across 
PubMed (https://www.ncbi.nlm.nih.gov/pubmed/advanced) and Google Scholar 
(https://scholar.google.co.za), during April – May 2018. Variants were extracted from the whole-
genome data of the FES cohort (described later) using PLINK v1.90 
(http://pngu.mgh.harvard.edu/purcell/plink).  
 
2.6.3. Bioinformatic pathway analysis  
 
After the identification of genes targeted by the previously described mature 43 miRNAs (appendix, 
Supplementary Table 2) the genes were analyzed by Enrichr to categorize and identify relevant 
pathways according to gene ontology analysis as provided by this tool. Enrichr provides context of 
35 gene set libraries partitioned across six categories (pathways, ontologies, transcription, 
diseases/drugs, cell types and miscellaneous) for a library of genes. Enrichment is calculated using 
Fishers exact test (Fisher, 1970) assuming a binomial distribution and independence for probability 
of any gene belonging to any given set. The Z-statistic is utilized in determining the corresponding 
corrected p-values (Chen et al., 2013). The resultant pathways were stratified in the results by any 
relation to regulatory mechanisms, gene expression, pathways known with prior implication in SZ 




The results of the gene set enrichment analyses were separated into lists pertaining to genes shared 
across categorical databases and genes which were seen to be ‘unique’ (i.e. only appearing once) 
across databases. The top 20 gene enrichment categorical results displayed for the respective target 
genes are available in the appendix (Supplementary Tables 3 – 15). The bioinformatic pathway 
analyses result from M1 above was investigated in comparison to the enrichment output to confirm 
results and identify potential overlaps.  
 
Furthermore, an abundance of variants, including ~535 FES SNPs, were identified within the target 
genes of the 43 miRNAs. The Functional Mapping and Annotation of Genome-wide association 
studies (FUMA) tool (https://fuma.ctglab.nl) was used to annotate and interpret the SNPs in a 
SNP2GENE and GENE2FUNC analysis. SNP2GENE works to annotate either GWAS summary 
statistics or SNPs as input, functionally, followed by GENE2FUNC with the resultant input for 
biological context. The FUMA pipeline is described by the figure below, with the respective process 
used in this study outlined (Figure 2.4) (Watanabe et al., 2017). 
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Figure 2.4 FUMA pipeline (https://fuma.ctglab.nl/tutorial), with highlighted processes used 












3.1. (M1) Candidate gene selection 
 
The microarray gene selection was prioritized by gene set enrichment, the relevant results of the 
appropriately selected databases and the corresponding categorical enrichment gene sets from Enrichr 
are shown below (Table 3.1). Those pathways with pre-identified implications in neurological 





















Table 3.1 Predicted gene enrichment categories for candidate gene selection as defined by Enrichr 
Enrichr available at: http://amp.pharm.mssm.edu/Enrichr/, accessed on: March 2018. Bold typeset denotes selected genes; p-value threshold was selected as p < 5 x 10-2, significant p-
values are highlighted above. 
Gene Set Enrichment Analysis 
Database Category/Target/Pathway p-value Genes 
GO Molecular Function Histone deacetylase activity H3-K14 
specific 
7.495e-29 MBD3, HDAC4, HDAC5, HDAC2, HDAC3, HDAC10, HDAC1, 
HDAC11, CHD4, HDAC8, HDAC9, HDAC6, SAP30, RBBP4, 
SIN3A, SAP18, RBBP7 
Reactome Epigenetic regulation of gene 
expression 
7.114e-21 MBD3, DNMT1, HDAC2, HDAC1, DNMT3A, MBD2, CHD4, ACTB, 
SAP30, RBBP4, SIN3A, DNMT3B, SAP18, RBBP7 
Wikipathways Neural crest differentiation 5.710e-16 HDAC4, HDAC5, HDAC2, HDAC3, HDAC10, HDAC1, HDAC11, 
HDAC8, HDAC9, HDAC6, HDAC7 
GO Biological Process Negative regulation of transcription 
from RNA polymerase II promotor 
4.777e-10 HDAC4, MBD3, HDAC5, HDAC2, HDAC3, HDAC10, HDAC1, 
MBD2, CHD4, HDAC8, HDAC9, HDAC6, MECP2, SIN3A, 
DNMT3B, SAP18 
GO Molecular Function Histone deacetylase activity 2.842e-25 MBD3, HDAC4, HDAC5, HDAC2, HDAC3, HDAC10, HDAC1, 
HDAC11, CHD4, HDAC8, HDAC9, HDAC6, SAP30, RBBP4, 





GO Molecular Function 
 
Histone deacetylase activity H4-K16 
specific 
2.434e-28 MBD3, HDAC4, HDAC5, HDAC2, HDAC3, HDAC10, HDAC1, 
HDAC11, CHD4, HDAC8, HDAC9, HDAC6, SAP30, RBBP4, 
SIN3A, SAP18, RBBP7 
NAD-dependent histone deacetylase 
activity 
2.248e-28 MBD3, HDAC4, HDAC5, HDAC2, HDAC3, HDAC10, HDAC1, 
HDAC11, CHD4, HDAC8, HDAC9, HDAC6, SAP30, RBBP4, 
SIN3A, SAP18, RBBP7 
Histone deacetylase activity H3-K9 
specific 
2.086e-28 MBD3, HDAC4, HDAC5, HDAC2, HDAC3, HDAC10, HDAC1, 
HDAC11, CHD4, HDAC8, HDAC9, HDAC6, SAP30, RBBP4, 
SIN3A, SAP18, RBBP7 
Jensen DISEASES Intellectual disability 0.1541 MECP2, HDAC4, DNMT3A, HDAC8, ACTB 
TargetScan microRNA 
 
hsa-miRNA-3618 0.1148 MECP2, HDAC4, HDAC2, HDAC3, MBD2, DNMT3B, SAP18, 
GAPDH, HDAC9, TRDMT1 
miRTarBase hsa-miRNA-92a-3p 0.1033 MECP2, DNMT1, HDAC2, HDAC1, SIN3A, MBD2, RBBP7, 
GAPDH, ACTB, SAP30 
TargetScan microRNA 
 
hsa-miRNA-4536 0.09676 MECP2, HDAC4, HDAC5, HDAC2, DNMT3A, DNMT3B, HDAC7 









HDAC3, RBBP4, RPLP0, SAP18 
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A total of 12 candidate genes from the TaqMan microarray were selected for further 
inclusion. The genes and relevant genomic locations are shown below (Table 3.2).  
 
Table 3.2 Candidate genes prioritized  
 
*Chr: chromosome; **GRCh37.p13: Human Genome Assembly version 37  
 
3.2. (M1) Variant identification 
 
In summary, the candidate approach resulted in 12 of the TaqMan Microarray genes being 
prioritized for inclusion in this study, with a total of 326 known variants identified, 12 of which 
were annotated with genotype data for the FES cohort. These variants were further prioritized 
by MAF 0.05 for inclusion and further downstream association analyses, this threshold was 
chosen to include commonly occurring variants in our cohort. A resultant six SNPs were 
considered for further analyses; rs16835131, rs895808, rs352068, rs17348528, rs3088071 and 
rs375171. The SNPs were identified in four histone deacetylase (HDAC) genes, the Sin3A 
associated protein (SAP) gene, the retinoblastoma binding protein four (RBBP4) gene and the 









Gene Chr GRCh37.p13** location 
HDAC1 1 32757708..32799227 
HDAC2 6 114257320..114292359 
HDAC3 5 141000443..141016423 
HDAC4 2 239969864..240323346 
HDAC5 17 42154121..42201014 
HDAC6 X 48660086..48683408 
HDAC8 X 71549366..71792953 
HDAC9 7 18126572..19039135 
SAP18 13 21714653..21723224 
SAP30 4 174292093..174298683 
SIN3A 15 75661720..75748181 
RBBP4 1 33116749..33151812 
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Table 3.3 Summary of relevant genetic variants 
 achr;bp = chromosome: base pair; A1: alternate allele ; A2: ancestral allele ; UTR: untranslated region 
 
The selected variants were investigated with PolymiRTs for their predicted miRNA-related 
impact and were annotated as function class C, D, or N (Table 3.4). The respective classes 
annotate variants as follows, C; the derived allele creates a new miRNA binding site, D; the 
derived allele disrupts a conserved miRNA site, and N; the derived allele disrupts a non-
conserved miRNA site. Although some predictions are of variants with effect in non-conserved 
sites (N) and hence have lesser weighted impact in terms of effect, these were the only 
predictions and annotation available as identified with this bioinformatic platform. The 
highlighted miRNA, hsa-miR-130a-5p, overlapped between M1 and M2, as it an input miRNA 



















1;33148935 A G 3'-UTR, 
intronic 
rs895808 HDAC4 2;239970360 G T 3'-UTR 
rs352068 HDAC2 6;114261852 G A Non-coding 
rs17348528 HDAC9 7;18706703 C T Intronic  
rs3088071 SAP18 13;21722557 G A 3'-UTR 
rs375171 HDAC5 17;42154470 C T 3'-UTR 
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Table 3.4 PolymiRTs prediction output and identification of variants 
 
 *Linked to miRbase. Functional class identifiers; D: the derived allele disrupts a conserved miRNA site (ancestral 
allele with support >= 2), C: The derived allele creates a new miRNA site, N: The derived allele disrupts a non-
conserved miRNA site (ancestral allele with support < 2). Bold typeset indicated miRNA ID, is a shared miRNA 
from Hauberg et al., (2016). PolymiRTs available at: http://compbio.uthsc.edu/miRSNP/; accessed on: March 
2018.    
 
3.3. (M1) Bioinformatic analyses  
 
When annotating variants, RegulomeDB assigns a score to each resultant output. A score of 
1 to 6 is allocated with descriptions for scores 1 – 3; “likely to affect binding and linked to 
expression of target gene” and “minimal binding evidence”, and a score of 4 – 6 indicating 
minimal binding evidence (Boyle et al., 2012). All variants displayed minimal to no binding 
evidence in RegulomeDB scoring (Table 3.5). According to rSNPBase, five out of the six 
variants displayed evidence for proximal regulation and three with evidence of distal regulation 
PolymiRTs SNP ID Gene ID miR ID* Function Class* 
rs16835131 RBBP4 
SYNC 
hsa-miR-7974  D 
rs895808 HDAC4 hsa-miR-548ac 
hsa-miR-548d-3p 
hsa-miR-548h-3p 





rs352068 HDAC2 hsa-miR-130a-5p 
 hsa-miR-23a-3p  
hsa-miR-23b-3p  









rs17348528 HDAC9 hsa-miR-4684-3p  C 








































(Guo et al., 2014b). None of the SNPs had evidence towards miRNA regulation however five 
out of the six displayed evidence with RNA binding protein mediated regulation. Lastly five 
variants were reported as eQTL by rSNPBase (Guo et al., 2014b). Variants with assigned 
scores in relation to these predicted regulatory effects, are described below (Table 3.5). 
 
Table 3.5 Functional and regulatory impact of variants  
 aResults range from 1 to 6 with descriptions of “likely to affect binding and linked to expression of target gene” 
and “minimal binding evidence”: 4/5/6 = Minimal binding evidence; b yes = involved, and no = not involved in 
regulation; eQTL = expression quantitative trait loci; miRNA = microRNA. RegulomeDB available at: 
http://www.regulomedb.org/index; rSNPBase available at: http://rsnp.psych.ac.cn/index.do, both accessed on: 
May 2019.  
 
SNPnexus was utilized to corroborate functional impact of the identified variants 
(Dayem Ullah et al., 2018). Predicted protein functional effects are based on 
the SIFT and PolyPhen predictions (Adzhubei et al., 2010; Kumar et al., 2009), however no 
results were returned when the database was queried (available at: https://snp-



































5 No No No Yes Yes 
rs895808 HDAC4 6 Yes No No No Yes 
rs352068 HDAC2 No data Yes Yes No Yes Yes 
rs17348528 HDAC9 No data Yes No No Yes No 
rs3088071 SAP18 4 Yes Yes No Yes Yes 
rs375171 HDAC5 4 Yes Yes No Yes Yes 
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Allelic frequencies were compared to Ensembl minor allele frequencies of the African, 
European, South Asian and East Asian populations and are shown below (Table 3.6). The 
Hardy-Weinberg Equilibrium (HWE) value for each variant was determined using SNPstats 
(Sole et al., 2006).  
 
Table 3.6 Comparative allele frequencies of variants 
aAll alternate (A2) allele frequencies; b - e Obtained from Ensembl 1000 Genomes Project Phase 3, available at: 
https://www.ensembl.org/index.html; f MAF: minor allele frequency, obtained using PLINK v1.90, gHW = Hardy-
Weinberg equilibrium value, as determined by SNPstats available at: https://snpstats.net/start.htm, both databases 
accessed on: May 2019. 
 
3.4. (M1) Association analyses with ATR 
 
Significant associations between variants and change in PANSS scores (positive, negative, 
general, and total) over the 12-month time period (adjusted as previously described) were 
investigated. Where significant findings were noted, mode of inheritance, odds ratios and 
confidence intervals were calculated (Table 3.7). After Bonferroni correction (p  1.04 x 10-3), 
one (rs895808) of the six variants survived multiple testing and was found significantly 
associated with antipsychotic treatment response. Considering the inheritance models used in 
this study, significant variants were seen to influence PANSS scores over time based on the 
presence of a particular genotype or allele respectively. Furthermore, this effect mediated by 



































G/A 0.05825 0.072 0.099 
 
0.104 0.092 1 
rs895808 HDAC4 A/C 0.3398 0.0290 0.303 0.371 0.282 0.27 
rs352068 HDAC2 T/C 0.05825 0.010 0.076 0.156 0.140 0.29 
rs17348528 HDAC9 T/C 0.1165 0.126 0.175 0.100 0.102 0.35 
rs3088071 SAP18 A/G 0.2864 0.225 0.716 0.452 0.422 0.031 
rs375171 HDAC5 G/A 0.3252 0.821 0.782 0.473 0.449 0.37 
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corresponding 95% confidence interval.  
Table 3.7 Variants trending to significance (p5 x10-2) associated with antipsychotic 
treatment response as per change in PANSS scores over 12 months, considering genotypic 
and additive modes of inheritance.  
 *p-value significance threshold (p0.05); bold typeset indicates variants passing original Bonferroni correction 




The majority of associations were noted in the negative PANSS domain under both genotypic 
and additive models of inheritance. One other association was determined in both the general 
and total PANSS domains, and none were found with significant effect of the positive symptom 
domain. Overall, all four variants (rs3088071, rs375171, rs895808, and rs352068) were 
associated with an improved treatment outcome (percentage change less than zero), although 
interestingly two variants, rs895808 and rs352068, were shown to be significantly associated 
with a worsened treatment outcome for the contrasting homozygous (GG) genotypes seen. 
When considering the additive mode of inheritance only two variants (rs895808 and rs352068) 
were found significantly associated with an improved treatment response (percentage change 
less than zero). Under the genotypic model the largest difference in percentage change between 
contrasting genotypes was seen for HDAC2 rs352068, which showed -0.42% change per month 
(p = 1.1 x 10-2) with the GG genotype (versus AA), indicative of the greatest improved response 
to treatment associated with a genotype. In contrast, the largest percent change value conferring 





















General  0.005 GA vs GG  
-0.07 
 -0.132 to -0.002 






0.003 GT vs GG 0.035 -0.034 to 0.103 






0.022 GA vs GG 0.04 -0.079 to 0.150 
0.011 GG vs AA -0.42 -0.770 to -0.064 






















each A -0.033 -0.134 to 0.068 
Total  0.0480 each A -0.014 -0.100 to 0.072 
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a worsened treatment response associated with a genotype, was observed for this same gene 
HDAC2 rs352068, which showed a 0.04% change per month (p = 2.2 x 10-2) for the alternate 
GA heterozygous genotype. 
 
Considering correction for multiple testing only one variant survived (rs895808) and was 
identified to have a significant association. This association was identified in HDAC4 and was 
determined to be significantly associated (p = 1.46 x 10-4) with an improved treatment response 
indicated by the -0.007% change for the T allele.  
 
3.5. (M1) Bioinformatic pathway analysis – NetworkAnalyst 
 
The subnetwork (subnetwork 2) denoted below refers to the interactions observed between the 
HDAC4 and HDAC2 genes. Visual representation of this subnetwork in gene-miRNA 
interactions are also displayed below (Figure 10). The nature of the microarray from which 
these genes were selected implies regulatory relevance and likely inclusion or influence of said 
processes. However, in context of this study the results reported below are representing the 
most relevant pathways with regard to miRNA-interaction or involvement (Table 3.8 – 3.13). 
 
Table 3.8 Gene-miRNA interaction for biological function 
Pathway p-value 
Chromatin remodeling 1.79x10-4 
Chromatin modification 3.75x10-3 
Regulation of transcription – DNA dependent 1.84x10-2 
Regulation of RNA metabolic process 2.04x10-2 
Gene silencing 2.06x10-2 
Regulation of gene expression – epigenetic 3.22x10-2 
Regulation of transcription from RNA 
polymerase II promotor 
3.51x10-2 
Notch signaling pathway 3.67x10-2 








Table 3.9 Gene-miRNA interaction for biological function (subnetwork 2) 
Pathway p-value 
Negative regulation of RNA metabolic 
process 
5.13x10-3 
Regulation of protein modification process 7.62x10-3 
Positive regulation of RNA metabolic 
process 
8.7x10-3 
Gene silencing 1.38x10-2 
Calcium-mediated signaling 1.49x10-2 
Regulation of gene expression – epigenetic 2.16x10-2 
Regulation of molecular function 2.47x10-2 
Response to drug 4.76x10-2 
 
Table 3.10 Gene-miRNA interaction for molecular function 
 
Pathway p-value 
Transcription corepressor activity 1.21x10-3 
Transcription cofactor activity 8.27x10-3 
 
Table 3.11 Gene-miRNA interaction for molecular function (subnetwork 2) 
 
Pathway p-value 
Transcription factor binding 1.23x10-3 
Negative regulation of transcription – DNA 
dependent 
4.64x10-3 
Positive regulation of transcription – DNA 
dependent 
7.54x10-3 
Transcription corepressor activity 2.85x10-2 
 




Notch signaling pathway 4.44x10-9 
Thyroid hormone signaling pathway 1.23x10-8 
MAPK signaling pathway 2.19x10-4 
Neurotrophin signaling pathway 5.78x10-4 
Huntington’s disease 2.31x10-3 
Cocaine addiction 2.85x10-3 
Wnt signaling pathway 3x10-3 
Long-term potentiation 8.74x10-3 
Amphetamine addiction 9.2x10-3 
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RNA transport 5x10-2 
 
Table 3.13 Transcription factor-miRNA coregulatory network for molecular function 
 
Pathway p-value 
Negative regulation of transcription – DNA 
dependent 
1.6x10-58 
Transcription corepressor activity 1.67x10-23 
 
Figure 3.1 Expected gene-miRNA interaction network for subnetwork 2 as determined by 






3.6. (M2) MiRNA gene target identification  
 
The miRNA-target prediction yielded 4536 target genes, reduced to 1515 genes once duplicates 
were removed.  
 
3.7. (M2) MiRNA target gene variant identification 
 
Within the above targets ~65200 known variants were identified, 525 of which are genotyped 
and annotated within the genome-wide genotype data for the FES cohort, and of those 435 
presenting with a MAF  0.05, this threshold was chosen to include commonly occurring 
variants in our cohort.  
 
3.8. (M2) Bioinformatic pathway analysis  
 
The following table (Table 3.14) displays the results of the gene set enrichment done in Enrichr, 
alongside the chosen databases and pathways of interest. Categories within respective 
databases were selected based on both p-value significance and with relevance to biological 
processes previously linked to SZ and those involving miRNA mechanisms. 
 
The FUMA analyses involved the 535 SNPs as input, all SNPs were annotated with a GWAS 
significant p-value (p < 5 x 10-8) with a sample size of 50000. As the annotation of the SNPs 
is the only value of interest in context of this study, these parameters are negligible for 
accuracy. Variants from a respective reference panel for LD analysis were not included in the 
analysis. The gene mapping result from the input SNPs is shown below (Figure 3.2) with 





Figure 3.2 Manhattan plot of gene-based test, for 154 genes mapped. 
 
Figure 3.3 Functional consequences of SNPs on genes 
 
The GENE2FUNC results were investigated in WikiPathways (Kelder et al., 2009) and all 
canonical pathways, also shown below (Figures 3.4 and 3.5). Any results from the GWAS 








Figure 3.4 WikiPathways results for GENE2FUNC 
 






















Table 3.14 Gene enrichment categories for miRNA target genes as defined by Enrichr, for unique genes 
 
Gene Set Enrichment Analysis 





VARS, TP53RK, EHMT1, NOC2L, C14ORF166, RRP8, TSEN54, TRIM28, RNF111, CSNK1D, KARS, RRAGD, TFAM, TARS2, ZSCAN25, 
ZNF398, SET, AARS2, BAZ2A, PRDX1, WBSCR22, ZNF264, ZNF383, HARS2, NR2F6, MOV10, AGO4, AGO1, INTS5, INTS6, FARSA, 
RPS23, EZH2, AARS, BTG2, SMG1, CDKN1B, SRPR, NAT10, MED15, HIST2H2AC, HNF4A, TNKS1BP1, RIOK2, COX8A, PRMT5, 
PARP1, TET2, DIEXF, HIST2H2BE, AEBP2, CD44, SRRT, RPS27L, COX5A, ZNF226, BRF2, HIPK1, GATAD2B, SKI, MARS, PRPF31, 
ZNF354A, ZNF354B, ZNF692, CCNT2, RNU1-1, GTF2B, CASC3, APEH, SESN2, ZNF202, SUPT16H, RPS9, DIMT1, NRBP1, 
HNRNPUL1, GEMIN4, HIST1H2BB, ZNF792, DNMT1, PLD6, ZMAT5, ZNF664, CPSF7, SMURF2, NR4A1, CNOT11, NABP2, MDM2, 
PIN1, PHF19, DYRK2, DDX47, CHD9, WDR4, ADAR, CHD4, ZNF529, UBTF, ZNF385A, TGIF1, ELAC2, PPM1A, NUP50, BIRC5, 
ETF1, GTF3C1, GTF3C3, HIST1H2BJ, POLDIP3, BMS1, IGF2BP3, HNRNPA0, HNRNPA3, ARID3A, CARM1, POLR3H, POLR3K, 
TRMT61A, TNRC6B 




GTF2B, IPO5, RCC1, KPNA5, AP2M1, SUPT16H, AP1B1, ADAM10, VCP, CUL5, CTBP1, BAG4, JAG2, NR4A1, FGFR1, FEN1, 
HSP90AB1, MTR, HEY1, AP1G1, DLAT, AXIN1, PPP2R5A, VPS37B, PACS1, CANX, AKT1S1, CHMP7, AMER1, FURIN, ERBB3, SYVN1 
WikiPathways 
2016 
mRNA processing 1.117e-5 PPM1G, DHX15, RBM39, NONO, HNRNPAB, SUGP2 
NCI-Nature 2016 
Regulation of telomerase 2.840e-3 IFNAR2, PTGES3, SP3 
ATR signalling 2.840e-3 TIPIN, TIMELESS 
WikiPathways 
2016 





HSPA9, BTG2, BTG1, DIS3L, ENO1, PFKL 
RNA transport 5.682e-2 NMD3, CASC3, FXR2, PRMT5, ELAC2, GEMIN4, ACIN1 
WikiPathways 
2016 
BDNF signaling 1.124e-1 EGR1, KIDINS220, RANBP9, CFL1 
HumanCyc 2016 
Superpathway of pyrimidine 
deoxyribonucleotides de novo biosynthesis 
1.651e-1 
 
RRM2, CMPK1, NME3, NME4, CTPS1, TYMS 
KEGG 2016 
Transcriptional misregulation in cancer 
1.655e-1 
 
ZBTB17, TAF15, KMT2A, MLLT1, HOXA11, ELK4, PER2, MEIS1, EWSR1, ID2, HIST1H3G, WHSC1, HIST1H3B, BCL2L1 
Thyroid hormone signaling pathway 1.903e-1 ITGB3, SLC2A1, ATP2A2, ATP1A1, MED12L, BMP4, ITGAV 
NCI-Nature 2016 
Signalling events mediated by HDAC class 
III 
2.345e-1 TUBA1B, TUBB2A, HIST4H4 





BioCarta 2016 IGF-1 signaling pathway 5.477e-1 SRF 





The role of miRNA-mediated regulation and miRNA targeted genes associated with SZ, in 
antipsychotic treatment response, has elucidated to underlying mechanisms contributing to the 
genetics of this trait, including regulatory homeostasis. The novel bioinformatic approach presented 
here provides the predicted regulatory impacts of variants and a picture of regulatory potential both 
of the identified variants as well as the mechanisms (i.e. miRNAs) involved.  
 
The global reach of miRNA-mediated mechanisms became clear upon the identification of an 
abundance of miRNA targets (~4k) and numerous SNPs in either method, amassing ~65k variants 
identified in miRNA target genes alone. Furthermore, in the investigation of variants influencing 
miRNA-binding/target sites in M1, an overlapping miRNA, hsa-miRNA-130a-5p, was found in the 
SZ working group of the PGC (Hauberg et al., 2016b). A variant within the HDAC2 gene was shown 
to create a binding site for this miRNA. The importance of considering overarching mechanisms in 
biological systems can be highlighted by the vast number of affected genes revealed in these analyses, 
as they represent potential feedback loops with regards to regulation and its downstream 
consequences. The involvement of such systems or pathways may underly mechanisms commonly 
overlooked, ignored or unknown in complex disorders and associated factors like ATR. 
 
The SNP, rs16835131 was identified occurring in the intronic region of the SYNC gene and in the 
3’-UTR of RBBP4. The syncoilin intermediate filament protein gene (SYNC) is a member of the 
intermediate filament family and is found at neuromuscular junctions, sarcolemma, and Z-lines and 
thought to be important for muscle fiber integrity (Poon et al., 2002). The chromatin remodeling 
factor, RBBP4 gene has been described as a core component of a heterochromatin complex, 
Polycomb Repressive Complex 2 (PRC2), which is responsible for di- and tri-methylation of lysine 
27 in histone H3 (H3K27me2/3) (Sudhalkar et al., 2018). Neither of these two genes appear in any 
literature associated with SZ, and the variant implicated appears to be novel in the context of SZ. 
Upon identification of this variant, the following miRNA was found to be affected; hsa-miR-7974, 





The SNP, rs352068 was identified within the noncoding region of the histone deacetylase gene, 
HDAC2, that belongs to Class I of the HDAC gene family. This family is divided by sequence 
homology into Class I HDACs (1, 2, 3, and 8) and Class IIa HDACs (4, 5, 7, and 9). Previous research 
has shown that the serotonin 5-HT2A and other monoaminergic receptors are heavily implicated in 
mechanisms surrounding ATR, with atypical antipsychotics having high affinity binding for such 
receptors (Wang et al., 2018). Another system largely implicated by such mechanisms is that of the 
glutamatergic system and the metabotropic glutamate 2 receptor (mGlu2). This receptor has been 
identified to have significant impact on cellular signaling, and electrophysiological and behavioural 
functioning which require 5-HT2A expression in cortical pyramidal neurons (Moreno et al., 2009). 
These two receptors have been seen to alter signaling pathways exerting opposite effects on psychosis 
and antipsychotic-like behaviors. Atypical drugs were seen to affect 5-HT2A receptor density with 
further implication for the associated antipsychotic effects, and opposingly induced repressive histone 
modifications at the promotor region of the mGlu2 gene (GRM2) (Kurita et al., 2012). The interactive 
findings of the 5-HT2A and mGlu2 receptors were described as 5-HT2A receptor-dependent 
modulation of promotor activity of HDAC2, leading to the proposal of inhibition of this gene as a 
likely therapeutic candidate for ATR efficacy mechanisms. The variant has been identified previously 
in schizophrenic patients, albeit of Han Chinese ancestry and not presenting with genome-wide 
significance in association analyses with SZ (Chen et al., 2015). The following miRNAs were found 
to create a new site when considering the G allele of rs352068; hsa-miR-130a-5p, hsa-miR-23a-3p, 
hsa-miR-23b-3p, hsa-miR-23c, while the A allele of the SNP disrupts conserved sites of miRNAs; 
hsa-miR-1279, and hsa-miR-5007-3p. Interestingly hsa-miR-130a-5p was identified by the PGC-SZ 
working group investigation as occurring within a SZ risk locus (Hauberg et al., 2016a).  
 
The intronic SNP, rs17348528 was identified in a Class IIa, HDAC gene, HDAC9. Schizophrenia-
specific deletions were observed in this gene and further implicated HDACs in SZ pathophysiology 
(Tam et al., 2010). It was also found that decreased expression of HDAC9 was correlated to increased 
occurrence of neuronal apoptosis (Morrison et al., 2006), and deletion of the gene was also found in 
association with a SZ mouse model (Lang et al., 2012a), and in adult post-mitotic neurons, with links 
to SZ (Lang et al., 2012b). Further literature identified the variant, rs76872642 within HDAC9 
associated with reasoning/problem solving (Nakahara et al., 2018).  Despite these lines of evidence, 
research on HDAC9 expression in the brain have contradicting results. High gene levels were 
identified upon initial gene cloning (Zhou et al., 2001), versus relatively low levels found expressed 
in rat brain tissue (Broide et al., 2007a), and again high expression of HDAC9a and HDAC9b found 
in normal brain tissue (Lucio-Eterovic et al., 2008). These inconclusive findings highlight the need 
for clarification of both expression and functioning of HDAC9 in the brain and implicated disorders 
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like SZ. Furthermore, when considering the mechanism of action of HDAC genes in relation to ATR, 
HDAC9 is of great importance as two variants (rs1178119 and rs11764843) were associated with 
poorer ATR outcomes (O’Connell et al., 2018). The C allele of the variant created a new miRNA 
binding/target site for hsa-miR-4684-3p.  
 
The 3’-UTR SNP rs3088071 was identified in the SAP18 gene. The SAP18 gene encodes the histone 
deacetylase complex subunit SAP18 – a component of the SIN3-repressing complex involved in 
enhancement of SIN3-HDAC1 mediated transcriptional repression, as it is known to be a part of SIN3 
histone deacetylase (SIN3-HDAC) complex (Deka and Singh, 2017). This gene also forms part of the 
apoptosis-and splicing-associated protein (ASAP) complex, known to be imperative for RNA 
metabolism and hence it may mediate gene expression to an extent (Deka and Singh, 2017). The 
involvement of SAP18 in these complexes alludes to the repressive nature of this gene in transcription, 
achieved in combination with the action of histone deacetylase, and is therefore also recognized for 
its involvement in deacetylation of histones (Deka and Singh, 2017; Zhang et al., 1998, 1997). 
Furthermore SAP18 was identified to have decreased expression when comparing a mouse model for 
22q11 deletion syndrome (22q11DS) versus a control (Df1/+ vs wild-type), although SAP18 was 
found to be outside the Df1 deletion region (Jurata et al., 2006). Those afflicted by 22q11DS are also 
known to suffer from SZ, with around 25% of 22q11DS sufferers being affected. Furthermore, the 
Df1/+ mouse displayed deficits in cognitive functioning mirroring those of SZ symptoms (Bassett et 
al., 2005; Murphy et al., 2000; Jurata et al., 2006). Identification of the activity-dependent 
neuroprotective protein (ADNP) uncovered its crucial role in neural tube closure and brain formation 
and further evidence provided by Schirer et al., revealed an interaction of ADNP with RNA splicing 
machinery (Pinhasov et al., 2003; Schirer et al., 2014). Upon investigation of proteins interacting 
with ADNP, SAP18 was found as an auxiliary component of the splicing-dependent multiprotein exon 
junction complex (EJC) (Gozes, 2018; Havugimana et al., 2012). This complex is found deposited at 
the splice junction on mRNAs and provides potential evidence of this interaction between SAP18 and 
ADNP via RNA splicing machinery and hence implicates SAP18 in proper cognitive development 
and functioning. The A allele consequentially created a new binding/target site for hsa-miR-126-3p 
and disrupted conserved sites for hsa-miR-1206, hsa-miR-452-5p, hsa-miR-4676-3p, hsa-miR-6853-
3p, and hsa-miR-892c-3p. 
 
The 3’-UTR SNP, rs375171 occurs in another histone deacetylase gene, HDAC5 which is known for 
critical roles in neuronal plasticity, survival and differentiation and binds to and represses myogenic 
transcription factors of the myocyte enhancer factor-2 (MEF-2) (Chawla et al., 2003). This gene was 
found to be differentially expressed when comparing SZ-subtypes (chronic vs FES vs controls) with 
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significant association with ATR in a South African cohort (O’Connell et al., 2019). However, this 
finding was reported for a different variant, rs11079983, with increased expression and in association 
with a poorer treatment outcome for the TT genotype (versus CC) when considering the PANSS-
negative domain (O’Connell et al., 2019). Concluding the findings of their differential expression 
analyses, the authors discussed the potential alteration of specific pathways, resultant of altered gene 
expression in reducing the expression of ASB16 and increasing ASB16-AS1 in the cerebellum. Such 
pathways are the ubiquitin-mediated and cytokine signaling pathways, and these results were noted 
with the TT genotype of rs11079983, with a suspected advantage for ATR (Kohroki et al., 2005; 
Babon et al., 2009). The identification of the variant rs375171 is accompanied by a host of predicted 
miRNA consequences (Table 3). New binding site creation and disruption of a conserved site being 
most notable considering the sensitivity of histone deacetylase genes to environmental influences 
themselves. This SNP T allele was predicted to create a new miRNA binding/target site for hsa-miR-
1270, hsa-miR-4254, hsa-miR-4308, hsa-miR-4683, and hsa-miR-620, whilst the C allele disrupts 
the conserved sites of hsa-miR-4292 and hsa-miR-6791-5p, and finally to disrupt of non-conserved 
sites for hsa-miR-4450, hsa-miR-4667-5p, hsa-miR-4700-5p, hsa-miR-6852-5p, hsa-miR-6857-5p, 
and hsa-miR-8089. 
 
Whilst there were a multitude of miRNAs identified, those of most relevance pertain to having 
creation of a new miRNA site or disruption of a conserved site by interaction of the variant identified, 
for the context of this study the significant SNP associated with ATR outcomes and the respective 
miRNAs will be discussed in detail.  
 
The only association that survived Bonferroni correction in the association analyses was in the 3’-
UTR of the HDAC4 gene. The SNP rs895808 was significantly associated with an improvement in 
treatment response when considering both the additive and genotypic mode of inheritance (p=1x10-3 
and p=14.6x10-6 respectively) and was observed as a reduction in PANSS negative scores. This gene 
amongst others is a member HDAC gene family, which are epigenetic regulators responsible for 
removing acetyl groups for DNA-histone compaction in regulation of transcription mechanisms 
(Weïwer et al., 2013b). Belonging to Class IIa, HDAC4 displays tissue specificity and translocation 
between the nucleus and cytoplasm, and has been shown associated with SZ in an Asian ancestry 
cohort (Kim et al., 2010). HDAC4 was shown amongst others, in a rat with varied expression across 
all major brain regions and was amongst the highest expressed HDACs (Broide et al., 2007b). This 
gene notably does not have a mechanism by which binding to DNA can occur directly, but rather 
interacts with transcription factors MEF2C and MEF2D to do so (Weïwer et al., 2013b). No evidence 
for association of the SNP, rs895808, with SZ could be identified in literature. HDAC4 is thought to 
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be involved in mediating neuronal apoptosis in cerebellar granule neurons (Bolger and Yao, 2005). 
As with all cells that function optimally, neurons must maintain a balance between synthesis and 
degradation of proteins (Schneider et al., 2017). The G allele variant disrupts conserved sites of hsa-
miR-548ac, hsa-miR-548d-3p, hsa-miR-548h-3p, and hsa-miR-548z, as well as having been linked 
to miRNA-4536. The disruption of the miRNA site may alter binding and consequentially affect gene 
expression of HDAC4 and other genes targeted by the miRNAs, with potential impact on crucial 
cellular functions. Given that the association found was regarding the negative symptom domain, a 
regulatory alteration may impact this alleviation in ATR.   
 
While the miRNA-548 family hasn’t been linked to schizophrenia in functional implications, the 
characterization of this miRNA family has been met with many difficulties in that this specific family 
evolved from a transposable element (Piriyapongsa and Jordan, 2007), and thus members of this 
family consequentially overlap in functionality and are likely to interact with one another (Liang et 
al., 2012). However the microRNA, miRNA-548ac has been uncovered with interesting findings in 
multiple sclerosis (Hecker et al., 2019). Hecker et al., (2019) identified putative gene targets of 
miRNA-548ac, including DNAJC3 and HERPUD1, which are known to promote inflammatory 
responses and/or the folding and degradation of proteins. Neuroinflammation has been well 
established in the pathophysiology of schizophrenia, with pro-inflammatory cytokines reported in 
immunological findings (Smith and Maes, 1995), this presents a potential avenue for underlying 
miRNA-mediated regulatory effects to be investigated in treatment response of SZ. The additional 
miRNAs of the miRNA-548 family listed above returned no significant results for functionality in 
relation to any neurodevelopmental disorders and hence require further investigation in this context.  
Further validation would be required to observe these interactions to confirm hypotheses, however 
dysregulation could impede downstream biological pathways implicated in ATR.  
 
The regions in which the above variation occurred are also important to note, considering potential 
impact on miRNA-mediated regulation, however, seemingly obvious regions like the 3’-UTR are not 
the only regions of considerable significance. Genes which may have involvement in miRNA 
biogenesis and in pri-, pre-, and mature miRNA sequences, and hence variation within them, may 
also be implicated in this regulatory mechanism (Zhang et al., 2015). The 3’-UTR is of particular 
interest as variation occurring within a miRNA target site may depict a more pathway-specific effect 
downstream (Mishra and Bertino, 2009). A disruption in a conserved miRNA site may cause loss of 
ordinary repression control, which in itself has implications for gene expression mechanisms and 
potential knock-on effects underlying ATR mechanisms. Disruption to non-conserved sites however, 
present a difficulty regarding the degree to which these polymorphisms influence global mechanisms 
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such as miRNA-mediated regulation. The creation of a new miRNA site however could affect the 
expected gene expression patterns of that targeted mRNA. All the above SNPs, but one (rs16835151), 
was predicted to influence proximal regulation. None of the SNPs were predicted with miRNA 
regulation however most (all excluding rs895808) appeared to be predicted with RNA binding-
protein mediated regulation. Half the identified SNPs (rs352608, 3088071, and rs376171) had 
predicted distal regulatory associations and all but one (rs17348528) presented with eQTL evidence.  
 
The pathway analyses revealed concurrent themes of both regulation and the dysregulation of 
transcription, translation and associated factors, that may be represented by transcriptional 
homeostasis and dysregulation of transcription respectively. However, the pathway analysis was only 
considered in interaction with miRNA mechanisms as the original microarray was composed for 
transcriptional regulation. Many neuropsychiatric disorders like SZ have underlying interneuron 
transcriptional dysregulation (Lewis and Hashimoto, 2007). During development and learning the 
brain is composed of neurons that must elicit some plasticity in continuation of normal functioning 
whilst neurogenesis is occurring, and synaptic connections between the neurons are developing, 
strengthening, being altered and pruned (Ramocki and Zoghbi, 2008). Therefore, neurons within 
affected networks are required to make homeostatic responses to re-establish a balance between 
excitation and inhibition. Clinical studies have shown that loss or gain in dosage of proteins or RNAs 
in different neurodevelopmental disorders often result in similar or overlapping sets of neurological 
symptoms, which has been suggestive of molecules involved in cognitive and behavioral processes 
partaking in highly regulated homeostatic mechanisms (Ramocki and Zoghbi, 2008).  
 
The mechanism of miRNA-mediated regulation provides a potential feedback loop of regulation by 
which there may be association of these underlying mechanisms in the ATR of SZ. Subnetwork 2 
illustrates two ATR associated genes linked to miRNAs implicated in shared and individual 
regulation of these genes. These miRNAs were additional to those identified in this study however it 
substantiated how vast the spectrum of miRNAs responsible for a singular gene are and therefore 
their global reach. The FUMA pathway analysis results identified implicated pathways that are 
potential avenues for miRNA-mediated regulation as said genes were targeted by known SZ risk loci 
miRNAs. The WikiPathways results relevant for this study are; the regulation of apoptosis by 
parathyroid hormone-related protein, apoptosis and phosphodiesterase’s in neuronal function. These 
influences are of importance due to altered apoptosis implicated in abnormal neurodevelopment as 
well as neurodegenerative processes (Gassó et al., 2014). Synaptic or neuronal deficits may be alluded 
to an increased susceptibility to apoptosis as seen in SZ patients (Jarskog et al., 2005). Despite this 
evidence of involvement in SZ pathophysiology, apoptosis is yet to be investigated in context of 
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ATR, with these results indicating a potential avenue for exploration in the alleviation of ATR. 
Phosphodiesterase’s are key enzymes in cellular signaling pathways, and in reducing cyclic Mono 
Phosphate (cAMP) and/or cyclic Guanosine Mono Phosphate (cGMP) (Halene and Siegel, 2007).  
The mechanism of action of currently used antipsychotics is via antagonism of the D2 receptor. Upon 
the binding of dopamine to a receptor subtype a cascade of events result in a decrease of adenylyl 
cyclase activity, reducing cAMP formation and activation of Protein Kinase A (PKA) (Halene and 
Siegel, 2007). PKA activity has been observed to produce therapeutic benefits of AP treatment, with 
phosphorylation of various intracellular substrates depending heavily on this pathway activation. AP 
drugs are thought to oppose this action of dopamine at the D2 receptor and increase cAMP levels and 
downstream effects, indicative of a functional cAMP signal transduction pathway necessary for AP 
drug action (Burris et al., 2002). In the review compiled by Halene and affiliates (2007), 
phosphodiesterase inhibitors are highlighted as potential therapeutic targets, this interaction with 
miRNA-mediated regulation may hold potential for ATR in related pathways as identified. The 
Canonical Pathways analysis results had some relation to the above WikiPathways, with the intrinsic 
pathway for apoptosis and PKA activation in glucagon signaling amongst others. AP drugs have been 
investigated regarding influence on relevant pathways as they can regulate intracellular signaling 
molecules which in turn regulate signaling pathways (Huang and Song, 2019). The targeting by 
miRNA offers a mediated regulatory cascade for pathways that may underlie ATR mechanisms and 
hence offer therapeutic targets.  
 
Finally, this research can contribute to the knowledgebase on African patients. African populations 
have been underrepresented in neuro- and pharmacogenomics research in the past  (Quansah and 
McGregor, 2018). Despite evidence regarding the clear burden of non-communicable diseases in 
Africa, of which NP disorders are amongst the most prevalent, an enormous under-representation of 
African ancestry in large-scale neurogenomic studies remains (Mayosi et al., 2009b; Quansah and 
McGregor, 2018; Sirugo et al., 2019). As little as 11.1% of 569 neurogenomic studies was found to 
be representative of African ancestry cases (Quansah and McGregor, 2018). More recently however, 
the current GWAS catalogue showed a despairingly small representation of ancestry categories with 
as little as 2% of individuals reported of African ancestry (Figure 16) (Sirugo et al., 2019). The large 
variation attributed to intra- and inter-population substructure contributes to the identification of 
associations and potential drug response factors in complex disorders, in African individuals, and 
needs to be explored with inclusion of cohorts of African ancestry (Campbell and Tishkoff, 2008; 
Tishkoff et al., 2009a). This variation presents additional problems that consequentially extend to 
those already faced in targeted therapies and precision medicine development in Africa. Lower socio-
economic classes like those found in Africa are limited by both availability of the best treatment 
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options as well as the options themselves – both in treatment efficacy and potential adverse effects of 
the available drugs (Campbell and Tishkoff, 2008; Daar et al., 2007; Warnich et al., 2011a).  
 
Figure 4.1 GWAS by ancestry for studies in GWAS catalog through January 2019 (Sirugo et al., 
2019). Reprinted with permission from Elsevier 
 
Moreover the few pharmacogenomic studies that have been performed regarding South African 
populations have largely been based on candidate genes in relatively small cohorts and focus on 
different diseases of interest such as HIV and tuberculosis (Warnich et al., 2011b; Chimusa et al., 
2013; Swart et al., 2016). With such limited inclusion in large-scale research and the likelihood that 
GWAS allele frequencies may vary by 20 to 40-fold between population groups (Adeyemo and 
Rotimi, 2010), resultant outputs may not always be applicable to African populations. All of the above 
evidence and factors necessitate an important need for further pharmacogenetic research in diverse 
African, and South African, populations to better understand the underlying mechanisms of NP 
disorders and to aid in the development of effective treatment, with the aim of lessening the socio-




African populations and their importance in genomics research has been well established. Since these 
genetically diverse ethnic population groups are vital for fully understanding the genetic basis of NP 
disorders and respective drug treatments, the exclusion of such populations will likely exacerbate 
health inequalities (Sirugo et al., 2019). The wide-ranging history of the exploration of southern 
Africa resulted in varied genomes of the individuals residing there – extending from ancient and 
genetically diverse, to highly admixed and more recently, homogenous (Warnich et al., 2011a). It is 
well-known that the age of African populations contributes to their considerable genetic diversity.  
These populations having been exposed to fewer founder effects, varying diets, climates, infectious 
diseases, and geography resulted in the highest observed levels of within-population genetic diversity 
(Cavalli-Sforza, 1997; Campbell and Tishkoff, 2008; Warnich et al., 2011a). As such, individuals of 
African ancestry constitute the largest genetic variation among global populations. Consequentially, 
disregarding this variation in genomic research will negatively implicate the identification of potential 
risk loci and gene associations in complex NP disorders when inclusion of such individuals is limited 
(Quansah and McGregor, 2018; Warnich et al., 2011a). Given different evolutionary histories, 
different genetic mutations in the same gene may account for a given disease in diverse populations 
due to the phenomenon of allelic heterogeneity of complex illnesses (Botstein and Risch, 2003). 
However variation in causative mutations may thwart said disease diagnoses or subsequent treatment 
design (Sirugo et al., 2019). The replication of genetic associations across populations can be 
influenced by several factors, such as linkage disequilibrium (LD). Importantly, markers in LD with 
risk variants in Europeans may not necessarily be in LD in other, more diverse populations due to LD 
patterns reflecting differing demographic histories that vary across the globe (Sirugo et al., 2019). 
These differences in LD across ethnicities impact how well causal variation is captured by tagging 
SNPs identified in a single population. The “out-of-Africa” origin theory saw modern humans migrate 
out of Africa some 300k years ago, however African populations have maintained larger and more 
sub-structured populations and as a result more diverse LD patterns are seen across the continent  
(Tishkoff et al., 2009b).  
 
African populations are not only important to include in genomics research, but in pharmacogenetics 
research as well. Notably the antiretrovirals efavirenz (EFV) and rifampicin (RMP) used in 
HIV/AIDS and tuberculosis treatment were shown to alter miRNA and subsequent drug metabolizing 
enzyme genes (Swart and Dandara, 2019). Studies like this illustrates the necessity for inclusion of 
all aspects of pharmacogenetic contributors, as important drug metabolizing genes like CYP3A4, 
CYP3A5 and CYP2B6 are amongst those affected. Clinical implications for such findings are 
paramount, with interindividual differences attributing to drug metabolism and response prediction 




Warfarin is a commonly prescribed anticoagulant with dosage prescribed based on drug metabolizer 
genotype (Drozda et al., 2015). However, pharmacogenetic algorithms from trials based on primarily 
Caucasian and European populations only included specific variants in the vitamin K epoxide 
reductase complex 1 (VKORC1) gene, as well as within the cytochrome P450 2C9 (CYP2C9) gene 
(International Warfarin Pharmacogenetics Consortium, 2009). Importantly these warfarin dosage 
associated genes account for 40% of the interindividual dosage variability that is seen in the 
Caucasian population (Takeuchi et al., 2009). When investigating dosage effects of this drug in 
African populations, a staggering 26 novel CYP2C9 SNPs and only three previously described 
VKORC1 variants were identified in the South African black population (Mitchell et al., 2011). These 
findings have implications for the major drug metabolizer CYP family enzymes with different allelic 
combinations resulting in varied enzyme activity (Warnich et al., 2011b). Variation in both these 
genes, combined with a small subset of environmental factors, were found by Mitchell and colleagues 
(2011) to contribute to roughly 45% of the heterogeneity in warfarin dosage. The importance of 
population-specific pharmacogenetics has been reiterated when even a singular nucleotide 
polymorphism was shown to influence optimal dosage (Ndadza et al., 2019).  
 
Further population-specific diversity of the CYP family was illustrated with the CYP2D6 gene, an 
important metabolizer of approximately 20% of all prescribed medication, including antidepressants 
and antipsychotics (Goldstein, 2001). The highly polymorphic nature of this gene is well known and 
accounts for variable allele frequencies across different populations (Owen et al., 2009), with 
reiteration seen in the identification of novel, reduced function, and non-functional alleles across 
African populations (Dandara et al., 2014, 2001; Masimirembwa et al., 1996). High prevalence of a 
reduced function allele explained in part the large presence of those individuals classified as 
intermediate metabolizers in African populations (Masimirembwa et al., 1996; Gaedigk et al., 2008; 
Matimba et al., 2009), and confirms the uniqueness of African population genomes. The importance 
of this gene family in drug metabolism therefore has implications for the use of antipsychotics in said 
populations and these studies collectively illustrate the need for Afrocentric pharmacogenomic 
research (Dodgen et al., 2017).  
 
With specific regard to antipsychotic pharmacogenetic research, work has been done to better 
represent the genetic variability seen (Dandara et al., 2001). Drogemöller et al., (2014) performed 
exome sequencing on 11 Mixed-Ancestry (MA) South African FES patients followed by variant 
prioritization and genotyping of larger admixed FES and Xhosa case/control cohorts, respectively. 
The resultant identification of multiple loss-of-function variants encapsulated these unique 
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differences as the majority were either previously unidentified or occurred at dismissably low 
frequencies in Asian and European population groups (Drogemöller et al., 2014b). The development 
of the Southern African Human Genome project has also been an important addition to genomics 
research via characterization of 24 African genomes (Choudhury et al., 2017). Deep whole-genome 




The majority of the above described genes and identified variants occurred in noncoding regions of 
the genome, and with the majority of predicted miRNA effects occurring as disruptions of conserved 
sites or creation of new miRNA binding/target sites. Despite the prior knowledge of these genes 
implicated in regulation, it must be noted that these genes were assessed considering DNA 
methylation and transcriptional repression specifically, without miRNA-mediated regulatory 
mechanisms. It is clear that although few genes were selected for this study, multiple miRNAs were 
predicted to be affected in one way or another by variation in said genes. As suspected and in line 
with GWAS findings, most variation seen was either in noncoding or within the 3’-untranslated 
regions which reiterates the importance of said regions in annotation and interpretation of GWAS 
results. 
 
The association analyses above have identified novel variant associations to antipsychotic treatment 
outcomes, with the most significant findings in the negative symptom domain – which has been 
regularly and consistently difficult to treat and have alleviation for schizophrenic patients.  The ability 
of miRNAs to have wide effect on gene expression and functional pathways has shown to have 
implications in many psychiatric disorders, with schizophrenia characterized by dysregulation of 
multiple signaling pathways (Miller and Wahlestedt, 2010). The focus on miRNAs and miRNA-
mediated regulatory mechanisms in particular have shown an avenue to explain the dysregulation 
seen in said signaling pathways, with the pathway analyses above highlighting a common trend of 
transcriptional disruption. Further functional characterization of the miRNAs involved will allow for 
a more accurate targeting of strategies that can aim to restore whole gene network functionality and 
homeostatic balance in the context of antipsychotic treatment response.  Contextually all miRNAs 
identified could not be discussed, however the vast amount identified per so few genes reiterated the 
importance in understanding the underlying biological and molecular functions these dynamic 




The hypothesis-free approach in combination with the miRNA-target approach allowed for an 
identification of both concordance and discordance in the pathway analyses. Although overlap was 
already determined in the transcriptional capacity, many other interesting pathways were identified 
in the enrichment analyses that too have been related to schizophrenia previously, like the Wnt, 
neurotrophin, MAPK, Notch and thyroid hormone signaling pathways. Importantly this study 
reaffirmed that there are underlying mechanisms capable of interacting and influencing pathways and 
systems that may influence antipsychotic outcomes in neurodevelopmental disorders.  MiRNAs may 
influence specific pathways and systems that in turn are mediating responses seen in regulatory 
consequences and furthermore are representative of both the noncoding regions importance in large-
scale study designs as well as the environmental influence that persists in neurodevelopmental 
disorders like schizophrenia. Lastly in incorporating diverse population groups such as that in the 
FES cohort, adds to the very limited genomic data surrounding African populations, and allows for 
unique African profiles to be accurately and properly identified and assessed.  
 
5.1. STUDY LIMITATIONS 
 
This study primarily utilized bioinformatic strategies and in absence of RNA-seq data expression 
analyses were not possible. Therefore, the results that have been shown are predictive and open to 
further interpretation where possible functional validation would ideally confirm the findings. The 
ethnicities composed in the cohort presented difficulty in that there is a lack of accurate references 
available and hence a lack of imputation and a reduced number of SNPs available with genotype 
information. 
 
5.2. STUDY STRENGTHS 
 
Despite the size of the FES cohort it is however important to note the unique features of the cohort. 
The cohort is extremely well-characterized and homogenized, with all patients being treatment-naïve 
at the start of the study. Importantly all participants were administered the same LAI antipsychotic 
which ensured adherence to treatment. Smaller clinical cohorts of well-characterized individuals have 
been shown to have equivalent power to cohorts of larger size with less well-characterized patients 
(Samuels et al., 2009). First-episode cohorts have also shown to provide increased power in 
pharmacogenetic studies (Zhang and Malhotra, 2013b). With these factors in mind, this study 
minimized confounders and provided enough statistical power to detect associations (Reynolds, 
2007), which was further demonstrated by the surfacing of significant findings surviving multiple 
testing. Lastly this cohort was beneficial in that few other antipsychotic pharmacogenetic studies exist 
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with cohorts of similar size, albeit for one study which found and replicated a genome-wide signal in 
a cohort of comparable size (n = 139) (Malhotra et al., 2012a). 
 
5.3. FUTURE PERSPECTIVES 
 
While the large-scale studies like GWAS and massive consortia of combined efforts in the PGC 
working groups have amassed and contributed the majority of data and knowledge to the study of 
neuropsychiatric disorders, these studies do not encompass all aspects of underlying biology. It is 
most likely a combination of rare, common, and de novo variation (van Dongen and Boomsma, 2013), 
with additional systems genetics influencing implicated gene networks, that resultantly produce traits 
of such complexity like antipsychotic treatment response. A combined approach that encompasses all 
such variables, including functional validation studies, within larger GWAS-like cohorts should be 
the way forward. However, the obvious key is cohort size, even more-so when considering global 
mechanisms that may unveil more overarching mechanisms underlying complex traits, 
pharmacogenomic research can only hope to advance with the employment of PGC-comparable 
cohorts of thousands to tens of thousands of participants, as has already been shown (Schizophrenia 
Working Group of the Psychiatric Genomics Consortium, 2014).     
 
The generation of data from these working groups is massive, however little goes beyond 
identification of loci, or molecular entities (Hauberg et al., 2016a), the need for thorough 
interpretation, interrogation and investigation into functional and molecular aspects of such data is 
apparent by the lack of in vitro research models for antipsychotic treatment response in disorders like 
schizophrenia.  However, there is potential considering the likes of new technologies ability to 
develop induced pluripotent stem cell (iPSC)-derived neurons, in vitro studies of brain morphology 
under different states are viable.   Brennand and associates (2011) differentiated iPSCs into neurons 
for characterization of schizophrenia. The schizophrenia phenotype neurons showed diminished 
neuronal connectivity in conjunction with decreased neurite number, PSD95-protein levels, and 
diminished glutamate receptor expression (Brennand et al., 2011). Further gene expression profiles 
on the neurons revealed altered expression of components of the cyclic AMP and Wnt signaling 
pathways, and even more promising a pharmacogenetic finding of amelioration of key cellular and 
molecular components of the SZ phenotype by Loxapine. The identification of the Wnt signaling 
pathway may also allude to underlying mechanisms like that of miRNA-mediated regulation 
considering the results of the current study. However, studies of this nature can confirm predictive 





































*Applied Biosystems, California, USA 
 
Pathways description: Transcriptional repression is an essential mechanism in the precise control of 
gene expression. Transcriptional repressor proteins associate with their target genes either directly 
through a DNA-binding domain or indirectly by interacting with other DNA-bound proteins. To 
inhibit transcription in a selective manner, a repressor protein can (1) mask a transcriptional activation 
domain, (2) block interaction of an activator with other components of the transcription machinery, 
or (3) displace an activator from the DNA. Furthermore, DNA response elements can exert allosteric 
effects on transcriptional regulators, such that regulators may activate transcription in the context of 
one gene yet repress transcription in another. The most direct mechanism by which DNA methylation 
can interfere with transcription is to prevent the binding of basal transcriptional machinery or 
ubiquitous TF (Transcription Factors) that require contact with cytosine (C) in the major groove of 
the double helix. Transcriptionally active chromatin is predominantly unmethylated and has high 
# Assay IDs Gene 
2 Hs99999905_m1 GAPDH 
3 Hs99999909_m1 HPRT1 
4 Hs99999908_m1 GUSB 
5 Hs99999903_m1 ACTB 
6 Hs99999907_m1 B2M 
7 Hs99999902_m1 RPLP0 
8 Hs00609297_m1 HMBS 
9 Hs00172349_m1 CHD4 
10 Hs00154749_m1 DNMT1 
11 Hs01027166_m1 DNMT3A 
12 Hs00171876_m1 DNMT3B 
13 Hs02621185_s1 HDAC1 
14 Hs00368899_m1 HDAC10 
15 Hs00227335_m1 HDAC11 
16 Hs00231032_m1 HDAC2 
17 Hs00187320_m1 HDAC3 
18 Hs00195814_m1 HDAC4 
19 Hs00608366_m1 HDAC5 
20 Hs00195869_m1 HDAC6 
21 Hs00248789_m1 HDAC7 
22 Hs00218503_m1 HDAC8 
23 Hs00206843_m1 HDAC9 
24 Hs00969366_m1 MBD2 
25 Hs00172710_m1 MBD3 
26 Hs00172845_m1 MECP2 
27 Hs00428403_g1 RBBP4 
28 Hs00171476_m1 RBBP7 
29 Hs00705532_s1 SAP18 
30 Hs01009154_g1 SAP30 
31 Hs00411592_m1 SIN3A 
32 Hs00189402_m1 TRDMT1 
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levels of acetylated Histone tails. Most mammalian TFs have GC-rich binding sites, and many have 
CpGs in their DNA recognition elements. Binding by several of these factors is impeded or abolished 
by methylation of CpG. 
 
Supplementary Table 2. 43 mature miRNAs identified by PGC-SZ working group 
(Hauberg et al., 2016a) 
















































KEGG 2016 via Enrichr 
Term P-value Adjusted p-value Z score 
Cell cycle_Homo_sapiens_hsa04110 1.65x10-6 4.53 x10-4 -1.73 
Ribosome_Homo sapiens_hsa03010 11.2x10-6 1.55x10-4 -1.72 
Viral carcinogenesis_Homo sapiens_hsa05203 17x10-5 9.78x10-3 -1.93 
RNA degradation_Homo sapiens_hsa03018 18x10-5 9.78x10-3 -1.74 
Spliceosome_Homo sapiens_hsa03040 175x10-6 9.78x10-3 -1.72 
RNA transport_Homo sapiens_hsa03013 12.4x10-4 5.7x10-2 -1.74 
Proteoglycans in cancer_Homo sapiens_hsa05205 5.88x10-3 1.8x10-2 -1.80 
Protein processing in endoplasmic reticulum_Homo sapiens_hsa04141 
4.43x10-3 1.65x10-2 -1.67 
Prostate cancer_Homo sapiens_hsa05215 7x10-3 1.9x10-2 -1.71 
Transcriptional misregulation in cancer_Homo sapiens_hsa05202 
5x10-3 1.65x10-2 -1.58 
Thyroid hormone signaling pathway_Homo sapiens_hsa04919 
7.61x10-3 1.9x10-2 -1.59 
Biosynthesis of amino acids_Homo sapiens_hsa01230 9.32x10-3 2.13x10-2 -1.41 
Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 
1.56x10-2 2.86x10-1 -1.54 
Carbon metabolism_Homo sapiens_hsa01200 1.1x10-2 2.34x10-1 -1.40 
Chronic myeloid leukemia_Homo sapiens_hsa05220 
2.09x10-2 3.57x10-2 -1.44 
Ubiquitin mediated proteolysis_Homo sapiens_hsa04120 
1.54x10-2 2.86x10-2 -1.33 
Oocyte meiosis_Homo sapiens_hsa04114 2.34x10-2 3.57x10-2 -1.43 
Hippo signaling pathway_Homo sapiens_hsa04390 2.25x10-2 3.57x10-2 -1.35 
Pyrimidine metabolism_Homo sapiens_hsa00240 2.69x10-2 3.9x10-1 -1.29 
FoxO signaling pathway_Homo sapiens_hsa04068 4.4x10-2 4.76x10-1 -1.29 
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HumanCyc 2016 via Enrichr 
Term P-value Adjusted p-value Z score 
superpathway of pyrimidine deoxyribonucleotides de novo biosynthesis_Homo 
sapiens_PWY-7211 3.76x10-3 1.65x10-2 -2.04 
superpathway of conversion of glucose to acetyl CoA and entry into the TCA cycle_Homo 
sapiens_PWY66-407 68.4x10-4 1.65x10-2 -1.50 
tRNA charging_Homo sapiens_TRNA-CHARGING-PWY 6.7x10-3 1.65x10-2 -1.45 
glycolysis_Homo sapiens_PWY66-400 7.68x10-3 1.65x10-2 -1.15 
UTP and CTP de novo biosynthesis_Homo sapiens_PWY-7176 9.9x10-3 1.7x10-2 -1.18 
superpathway of pyrimidine ribonucleotides de novo biosynthesis_Homo sapiens_PWY0-
162 17.7x10-3 2.45x10-1 -1.13 
pyrimidine deoxyribonucleotides biosynthesis from CTP_Homo sapiens_PWY-7210 22.7x10-3 2.45x10-1 -1.03 
pyrimidine deoxyribonucleotides de novo biosynthesis_Homo sapiens_PWY-7184 22.7x10-3 2.45x10-1 -0.82 
superpathway of pyrimidine deoxyribonucleoside salvage_Homo sapiens_PWY-7200 28.5x10-3 2.73x10-1 -0.86 
superpathway of purine nucleotide salvage_Homo sapiens_PWY66-409 5.1x10-2 3.13x10-2 -0.04 
superpathway of tryptophan utilization_Homo sapiens_PWY66-401 9.5x10-1 9.5x10-1 10.9 
mucin core 1 and core 2 O-glycosylation_Homo sapiens_PWY-7433 8.9x10-1 9x10-1 13.1 
3-phosphoinositide biosynthesis_Homo sapiens_PWY-6352 8.8x10-1 9x10-1 12.3 
adenosine ribonucleotides de novo biosynthesis_Homo sapiens_PWY-7219 8.6x10-1 9x10-1 11.5 
D-myo-inositol (1,4,5)-trisphosphate biosynthesis_Homo sapiens_PWY-6351 8.6x10-1 9x10-1 12.1 
glutathione-mediated detoxification_Homo sapiens_PWY-4061 8.5x10-1 9x10-1 11.7 
guanosine nucleotides de novo biosynthesis_Homo sapiens_PWY-7228 10x10-2 4.46x10-1 0.99 
phospholipases_Homo sapiens_LIPASYN-PWY 7.94x10-1 8.53x10-1 11.2 
superpathway of inositol phosphate compounds_Homo sapiens_PWY-6371 7.67x10-1 8.45x10-1 10.3 










BioCarta 2016 via Enrichr 
Term P-value Adjusted p-value Z score 
Eukaryotic protein translation_Homo sapiens_h_eifPathway 30.1x10-6  5.42x10-3  -1.34 
Caspase Cascade in Apoptosis_Homo sapiens_h_caspasePathway 6.15x10-3  2.76x10-1  -1.37 
BTG family proteins and cell cycle regulation_Homo sapiens_h_btg2Pathway 3.03x10-3  2.72x10-1  -0.98 
Cell Cycle: G1/S Check Point _Homo sapiens_h_g1Pathway 11.5x10-3  2.96x10-2  -1.08 
CDK Regulation of DNA Replication_Homo sapiens_h_mcmPathway 9.22x10-3  2.76x10-2  -1.01 
Internal Ribosome entry pathway_Homo sapiens_h_iresPathway 9.22x10-3 2.76x10-2  -0.94 
HIV-1 Nef: negative effector of Fas and TNF_Homo sapiens_h_HivnefPathway 17.1x10-3  4x10-1  -1.05 
Cell Cycle: G2/M Checkpoint_Homo sapiens_h_g2Pathway 2.2x10-2 4x10-1 -0.91 
Apoptotic DNA fragmentation and tissue homeostasis_Homo 
sapiens_h_DNAfragmentPathway 7x10-3  3x10-1  -0.52 
Influence of Ras and Rho proteins on G1 to S Transition_Homo 
sapiens_h_RacCycDPathway 5.65x10-2  5.47x10-2  -0.89 
Telomeres, Telomerase, Cellular Aging, and  Immortality_Homo sapiens_h_telPathway 2.27x10-2  3.95x10-2  -0.59 
Cyclins and Cell Cycle Regulation_Homo sapiens_h_cellcyclePathway 26.4x10-3  3.95x10-2 -0.47 
IGF-1 Signaling Pathway_Homo sapiens_h_igf1Pathway 6x10-2  5.47x10-1  -0.35 
Chaperones modulate interferon Signaling Pathway_Homo sapiens_h_tidPathway 4.26x10-2  5.1x10-1  -0.20 
ATM Signaling Pathway_Homo sapiens_h_atmPathway 4.26x10-2 5.1x10-1 -0.10 
Phospholipids as signalling intermediaries_Homo sapiens_h_edg1Pathway 10x10-2  5.65x10-1  -0.06 
Actions of Nitric Oxide in the Heart_Homo sapiens_h_no1Pathway 9.63x10-1  9.63x10-1  7.53 
Ceramide Signaling Pathway_Homo sapiens_h_ceramidePathway 10x10-2  5.65x10-1  0.17 
Trefoil Factors Initiate  Mucosal Healing_Homo sapiens_h_tffPathway 13.3x10-2  6.15x10-1  0.24 
Chromatin Remodeling by hSWI/SNF ATP-dependent Complexes_Homo 











Reactome 2016 via Enrichr 
Term P-value Adjusted p-value Z score 
Gene Expression_Homo sapiens_R-HSA-74160 1.73x10-22  2.06x10-19  -2.15 
Infectious disease_Homo sapiens_R-HSA-5663205 2x10-13  2x10-10  -2.39 
Cell Cycle, Mitotic_Homo sapiens_R-HSA-69278 14.8x10-12  5.9x10-9  -2.45 
Cell Cycle_Homo sapiens_R-HSA-1640170 6.8x10-11  1.62x10-9  -2.42 
Translation_Homo sapiens_R-HSA-72766 2.67x10-11  8x10-9  -2.01 
Disease_Homo sapiens_R-HSA-1643685 12.4x10-9  1.23x10-7  -2.29 
Cap-dependent Translation Initiation_Homo sapiens_R-HSA-72737 10.2x10-10  1.73x10-8  -1.94 
Eukaryotic Translation Initiation_Homo sapiens_R-HSA-72613 10.2x10-10 1.73x10-8 -1.93 
Influenza Infection_Homo sapiens_R-HSA-168254 3.2x10-9  4.74x10-7  -2.02 
Cell Cycle Checkpoints_Homo sapiens_R-HSA-69620 2.7x10-8  1.85x10-7  -2.22 
Influenza Life Cycle_Homo sapiens_R-HSA-168255 5.87x10-9  7x10-7 -2.01 
GTP hydrolysis and joining of the 60S ribosomal subunit_Homo sapiens_R-HSA-
72706 4.2x10-9  5.53x10-7  -1.95 
Influenza Viral RNA Transcription and Replication_Homo sapiens_R-HSA-168273 1.9x10-8  1.52x10-7  -1.96 
Peptide chain elongation_Homo sapiens_R-HSA-156902 8.1x10-9  8.75x10-7  -1.87 
mRNA Splicing - Major Pathway_Homo sapiens_R-HSA-72163 1.55x10-8  1.42x10-7  -1.89 
Cellular responses to stress_Homo sapiens_R-HSA-2262752 1.64x10-7 7.51x10-6  -2.15 
mRNA Splicing_Homo sapiens_R-HSA-72172 2.56x10-8  1.85x10-6  -1.89 
Eukaryotic Translation Elongation_Homo sapiens_R-HSA-156842 2.8x10-8  1.85x10-6 -1.86 
Eukaryotic Translation Termination_Homo sapiens_R-HSA-72764 1.72x10-8  1.47x10-6  -1.81 













WikiPathways 2016 via Enrichr 
Term P-value Adjusted p-value Z score 
mRNA processing_Mus musculus_WP310 6.75x10-11  2.48x10-8 -2.13 
mRNA Processing_Homo sapiens_WP411 6.07x10-8  1.11x10-6  -1.94 
Cytoplasmic Ribosomal Proteins_Homo sapiens_WP477 5.5x10-7  6.75x10-5  -1.95 
Cytoplasmic Ribosomal Proteins_Mus musculus_WP163 13.4x10-6  1.24x10-4  -1.94 
Retinoblastoma (RB) in Cancer_Homo sapiens_WP2446 3.62x10-5  2.67x10-3  -1.84 
XPodNet - protein-protein interactions in the podocyte expanded by STRING_Mus 
musculus_WP2309 13.7x10-5  5.62x10-3  -2.01 
miRNA regulation of DNA Damage Response_Mus musculus_WP2087 6.67x10-5  4.1x10-3  -1.83 
Translation Factors_Homo sapiens_WP107 8.01x10-5  4.21x10-3  -1.85 
Translation Factors_Mus musculus_WP307 11.7x10-5  5.41x10-3  -1.70 
PluriNetWork_Mus musculus_WP1763 4.4x10-4  1.35x10-3  -1.89 
Cell Cycle_Homo sapiens_WP179 2.41x10-4  8.9x10-3  -1.66 
Androgen receptor signaling pathway_Homo sapiens_WP138 3.28x10-4  1.1x10-2  -1.63 
DNA Damage Response_Homo sapiens_WP707 4.89x10-4  1.38x10-3  -1.69 
PodNet: protein-protein interactions in the podocyte_Mus musculus_WP2310 9.09x10-4  2.4x10-2  -1.81 
Delta-Notch Signaling Pathway_Mus musculus_WP265 1x10-3 2.47x10-2  -1.59 
G1 to S cell cycle control_Mus musculus_WP413 1.57x10-3  3.63x10-2  -1.54 
Circadian rythm related genes_Homo sapiens_WP3594 2.43x10-3  3.86x10-2  -1.65 
Integrated Pancreatic Cancer Pathway_Homo sapiens_WP2377 2.77x10-3  3.86x10-2 -1.62 
miRNA Regulation of DNA Damage Response_Homo sapiens_WP1530 2.12x10-3  3.86x10-2 -1.52 













NCI-Nature 2016 via Enrichr 
Term P-value Adjusted p-value Z score 
Regulation of Telomerase_Homo sapiens_4dfe97ca-6195-11e5-8ac5-06603eb7f303 3x10-5  2.84x10-4  -1.64 
ATR signaling pathway_Homo sapiens_8991cbac-618b-11e5-8ac5-06603eb7f303 1.94x10-5  2.84x10-4 -1.43 
p53 pathway_Homo sapiens_a0de862d-6194-11e5-8ac5-06603eb7f303 6.69x10-5  4.22x10-3  -1.54 
Aurora B signaling_Homo sapiens_304a75af-618c-11e5-8ac5-06603eb7f303 1.04x10-4  4.94x10-3  -1.19 
Coregulation of Androgen receptor activity_Homo sapiens_27e0e369-6191-11e5-8ac5-
06603eb7f303 3.86x10-4  1.21x10-3  -1.32 
ATM pathway_Homo sapiens_49bc3e2b-618b-11e5-8ac5-06603eb7f303 1.46x10-4  5.54x10-3  -1.16 
mTOR signaling pathway_Homo sapiens_559dd850-6194-11e5-8ac5-06603eb7f303 5.72x10-4  1.35x10-3  -1.37 
E2F transcription factor network_Homo sapiens_bb4d0fd3-6191-11e5-8ac5-06603eb7f303 8.93x10-4  1.53x10-3  -1.30 
Validated targets of C-MYC transcriptional activation_Homo sapiens_61d3b115-6196-
11e5-8ac5-06603eb7f303 7.71x10-4  1.45x10-3  -1.22 
Notch-mediated HES/HEY network_Homo sapiens_8ee56389-6194-11e5-8ac5-
06603eb7f303 7.51x10-4  1.45x10-3 -1.12 
Notch signaling pathway_Homo sapiens_88f83518-6194-11e5-8ac5-06603eb7f303 1.35x10-3  2.13x10-2  -1.04 
Regulation of retinoblastoma protein_Homo sapiens_407a3468-6195-11e5-8ac5-
06603eb7f303 2.8x10-3  3.78x10-2  -1.10 
TGF-beta receptor signaling_Homo sapiens_1f188fcc-6196-11e5-8ac5-06603eb7f303 6.7x10-3  8.44x10-2  -0.93 
Regulation of nuclear SMAD2/3 signaling_Homo sapiens_246aac04-6195-11e5-8ac5-
06603eb7f303 7.6x10-3  8.5x10-2  -0.94 
Caspase Cascade in Apoptosis_Homo sapiens_b9d3ef2e-618f-11e5-8ac5-06603eb7f303 7.64x10-3  8.5x10-2 -0.90 
Aurora A signaling_Homo sapiens_f131cf8e-618b-11e5-8ac5-06603eb7f303 1.73x10-3  2.52x10-2  -0.57 
Validated nuclear estrogen receptor alpha network_Homo sapiens_58949883-6196-11e5-
8ac5-06603eb7f303 2.14x10-2  1.92x10-1  -0.70 
Trk receptor signaling mediated by PI3K and PLC-gamma_Homo sapiens_4037def0-6196-
11e5-8ac5-06603eb7f303 16.8x10-3  1.67x10-2  -0.55 
Circadian rhythm pathway_Homo sapiens_ffb11b85-6190-11e5-8ac5-06603eb7f303 5.15x10-4  1.35x10-3  -0.27 
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